-
1
-
-
0035499267
-
Stem cells, cancer, and cancer stem cells
-
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
-
(2001)
Nature
, vol.414
, pp. 105-111
-
-
Reya, T.1
Morrison, S.J.2
Clarke, M.F.3
Weissman, I.L.4
-
2
-
-
0030789242
-
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
-
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7.
-
(1997)
Nat Med
, vol.3
, pp. 730-737
-
-
Bonnet, D.1
Dick, J.E.2
-
3
-
-
0028091194
-
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
-
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-8.
-
(1994)
Nature
, vol.367
, pp. 645-648
-
-
Lapidot, T.1
Sirard, C.2
Vormoor, J.3
Murdoch, B.4
Hoang, T.5
Caceres-Cortes, J.6
Minden, M.7
Paterson, B.8
Caligiuri, M.A.9
Dick, J.E.10
-
4
-
-
33846095137
-
Identification and expansion of human colon-cancer-initiating cells
-
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-5.
-
(2007)
Nature
, vol.445
, pp. 111-115
-
-
Ricci-Vitiani, L.1
Lombardi, D.G.2
Pilozzi, E.3
Biffoni, M.4
Todaro, M.5
Peschle, C.6
De Maria, R.7
-
5
-
-
9244241576
-
Identification of human brain tumour initiating cells
-
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
-
(2004)
Nature
, vol.432
, pp. 396-401
-
-
Singh, S.K.1
Hawkins, C.2
Clarke, I.D.3
Squire, J.A.4
Bayani, J.5
Hide, T.6
Henkelman, R.M.7
Cusimano, M.D.8
Dirks, P.B.9
-
6
-
-
38349165576
-
Identification of cells initiating human melanomas
-
Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-9.
-
(2008)
Nature
, vol.451
, pp. 345-349
-
-
Schatton, T.1
Murphy, G.F.2
Frank, N.Y.3
Yamaura, K.4
Waaga-Gasser, A.M.5
Gasser, M.6
Zhan, Q.7
Jordan, S.8
Duncan, L.M.9
Weishaupt, C.10
-
7
-
-
0037388204
-
Prospective identification of tumorigenic breast cancer cells
-
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 3983-3988
-
-
Al-Hajj, M.1
Wicha, M.S.2
Benito-Hernandez, A.3
Morrison, S.J.4
Clarke, M.F.5
-
8
-
-
49249091523
-
Identification and characterization of ovarian cancer-initiating cells from primary human tumors
-
Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311-20.
-
(2008)
Cancer Res
, vol.68
, pp. 4311-4320
-
-
Zhang, S.1
Balch, C.2
Chan, M.W.3
Lai, H.C.4
Matei, D.5
Schilder, J.M.6
Yan, P.S.7
Huang, T.H.8
Nephew, K.P.9
-
9
-
-
34249980343
-
Identification and characterization of tumorigenic liver cancer stem/progenitor cells
-
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542-56.
-
(2007)
Gastroenterology
, vol.132
, pp. 2542-2556
-
-
Ma, S.1
Chan, K.W.2
Hu, L.3
Lee, T.K.4
Wo, J.Y.5
Ng, I.O.6
Zheng, B.J.7
Guan, X.Y.8
-
10
-
-
28244472369
-
Prospective identification of tumorigenic prostate cancer stem cells
-
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946-51.
-
(2005)
Cancer Res
, vol.65
, pp. 10946-10951
-
-
Collins, A.T.1
Berry, P.A.2
Hyde, C.3
Stower, M.J.4
Maitland, N.J.5
-
11
-
-
39449088496
-
Identification and expansion of the tumorigenic lung cancer stem cell population
-
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504-14.
-
(2008)
Cell Death Differ
, vol.15
, pp. 504-514
-
-
Eramo, A.1
Lotti, F.2
Sette, G.3
Pilozzi, E.4
Biffoni, M.5
Di Virgilio, A.6
Conticello, C.7
Ruco, L.8
Peschle, C.9
De Maria, R.10
-
12
-
-
34249332411
-
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
-
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67:4010-5.
-
(2007)
Cancer Res
, vol.67
, pp. 4010-4015
-
-
Beier, D.1
Hau, P.2
Proescholdt, M.3
Lohmeier, A.4
Wischhusen, J.5
Oefner, P.J.6
Aigner, L.7
Brawanski, A.8
Bogdahn, U.9
Beier, C.P.10
-
13
-
-
76549120193
-
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation
-
Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010;70:719-29.
-
(2010)
Cancer Res
, vol.70
, pp. 719-729
-
-
Kemper, K.1
Sprick, M.R.2
de Bree, M.3
Scopelliti, A.4
Vermeulen, L.5
Hoek, M.6
Zeilstra, J.7
Pals, S.T.8
Mehmet, H.9
Stassi, G.10
Medema, J.P.11
-
14
-
-
77956435394
-
Alpha2,3-Sialylation regulates the stability of stem cell marker CD133
-
Zhou F, Cui C, Ge Y, Chen H, Li Q, Yang Z, Wu G, Sun S, Chen K, Gu J, et al. Alpha2,3-Sialylation regulates the stability of stem cell marker CD133. J Biochem. 2010;148:273-80.
-
(2010)
J Biochem
, vol.148
, pp. 273-280
-
-
Zhou, F.1
Cui, C.2
Ge, Y.3
Chen, H.4
Li, Q.5
Yang, Z.6
Wu, G.7
Sun, S.8
Chen, K.9
Gu, J.10
-
15
-
-
60449087921
-
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features
-
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012-24.
-
(2009)
Gastroenterology
, vol.136
, pp. 1012-1024
-
-
Yamashita, T.1
Ji, J.2
Budhu, A.3
Forgues, M.4
Yang, W.5
Wang, H.Y.6
Jia, H.7
Ye, Q.8
Qin, L.X.9
Wauthier, E.10
-
16
-
-
84884557825
-
Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells
-
Wilson GS, Hu Z, Duan W, Tian A, Wang XM, McLeod D, Lam V, George J, Qiao L. Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. Stem Cells Dev. 2013;22:2655-64.
-
(2013)
Stem Cells Dev
, vol.22
, pp. 2655-2664
-
-
Wilson, G.S.1
Hu, Z.2
Duan, W.3
Tian, A.4
Wang, X.M.5
McLeod, D.6
Lam, V.7
George, J.8
Qiao, L.9
-
17
-
-
84867212473
-
Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells
-
Chow EK, Fan LL, Chen X, Bishop JM. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology. 2012;56:1331-41.
-
(2012)
Hepatology
, vol.56
, pp. 1331-1341
-
-
Chow, E.K.1
Fan, L.L.2
Chen, X.3
Bishop, J.M.4
-
18
-
-
57349143739
-
Efficient tumour formation by single human melanoma cells
-
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593-8.
-
(2008)
Nature
, vol.456
, pp. 593-598
-
-
Quintana, E.1
Shackleton, M.2
Sabel, M.S.3
Fullen, D.R.4
Johnson, T.M.5
Morrison, S.J.6
-
19
-
-
35348837163
-
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma
-
Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007;25:2524-33.
-
(2007)
Stem Cells
, vol.25
, pp. 2524-2533
-
-
Bar, E.E.1
Chaudhry, A.2
Lin, A.3
Fan, X.4
Schreck, K.5
Matsui, W.6
Piccirillo, S.7
Vescovi, A.L.8
DiMeco, F.9
Olivi, A.10
Eberhart, C.G.11
-
20
-
-
33750814849
-
Angiogenesis-independent tumor growth mediated by stem-like cancer cells
-
Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A. 2006;103:16466-71.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 16466-16471
-
-
Sakariassen, P.O.1
Prestegarden, L.2
Wang, J.3
Skaftnesmo, K.O.4
Mahesparan, R.5
Molthoff, C.6
Sminia, P.7
Sundlisaeter, E.8
Misra, A.9
Tysnes, B.B.10
-
21
-
-
68349130357
-
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
-
Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15:907-13.
-
(2009)
Nat Med
, vol.15
, pp. 907-913
-
-
Lim, E.1
Vaillant, F.2
Wu, D.3
Forrest, N.C.4
Pal, B.5
Hart, A.H.6
Asselin-Labat, M.L.7
Gyorki, D.E.8
Ward, T.9
Partanen, A.10
-
22
-
-
77956218241
-
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells
-
Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010;7:403-17.
-
(2010)
Cell Stem Cell
, vol.7
, pp. 403-417
-
-
Molyneux, G.1
Geyer, F.C.2
Magnay, F.A.3
McCarthy, A.4
Kendrick, H.5
Natrajan, R.6
Mackay, A.7
Grigoriadis, A.8
Tutt, A.9
Ashworth, A.10
-
23
-
-
80052468964
-
Stem cell gene expression programs influence clinical outcome in human leukemia
-
Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086-93.
-
(2011)
Nat Med
, vol.17
, pp. 1086-1093
-
-
Eppert, K.1
Takenaka, K.2
Lechman, E.R.3
Waldron, L.4
Nilsson, B.5
van Galen, P.6
Metzeler, K.H.7
Poeppl, A.8
Ling, V.9
Beyene, J.10
-
24
-
-
33749335282
-
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease
-
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929-35.
-
(2006)
Science
, vol.313
, pp. 1929-1935
-
-
Lamb, J.1
Crawford, E.D.2
Peck, D.3
Modell, J.W.4
Blat, I.C.5
Wrobel, M.J.6
Lerner, J.7
Brunet, J.P.8
Subramanian, A.9
Ross, K.N.10
-
25
-
-
79952213086
-
Using a stem cell-based signature to guide therapeutic selection in cancer
-
Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011;71:1772-80.
-
(2011)
Cancer Res
, vol.71
, pp. 1772-1780
-
-
Shats, I.1
Gatza, M.L.2
Chang, J.T.3
Mori, S.4
Wang, J.5
Rich, J.6
Nevins, J.R.7
-
26
-
-
34249279527
-
Stability and flexibility of epigenetic gene regulation in mammalian development
-
Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature. 2007;447:425-32.
-
(2007)
Nature
, vol.447
, pp. 425-432
-
-
Reik, W.1
-
27
-
-
0035962649
-
Role of protein methylation in chromatin remodeling and transcriptional regulation
-
Stallcup MR. Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene. 2001;20:3014-20.
-
(2001)
Oncogene
, vol.20
, pp. 3014-3020
-
-
Stallcup, M.R.1
-
28
-
-
33847076849
-
Chromatin modifications and their function
-
Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693-705.
-
(2007)
Cell
, vol.128
, pp. 693-705
-
-
Kouzarides, T.1
-
29
-
-
84930654453
-
Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries
-
Wongtrakoongate P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J Stem Cells. 2015;7:137-48.
-
(2015)
World J Stem Cells
, vol.7
, pp. 137-148
-
-
Wongtrakoongate, P.1
-
30
-
-
34547792388
-
Epigenetic gene silencing in cancer: the DNA hypermethylome
-
Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16 Spec No 1:R50-59.
-
(2007)
Hum Mol Genet
, vol.16
, pp. R50-59
-
-
Esteller, M.1
-
31
-
-
33846569960
-
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
-
Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 2007;39:237-42.
-
(2007)
Nat Genet
, vol.39
, pp. 237-242
-
-
Ohm, J.E.1
McGarvey, K.M.2
Yu, X.3
Cheng, L.4
Schuebel, K.E.5
Cope, L.6
Mohammad, H.P.7
Chen, W.8
Daniel, V.C.9
Yu, W.10
-
32
-
-
33847065486
-
The epigenomics of cancer
-
Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-92.
-
(2007)
Cell
, vol.128
, pp. 683-692
-
-
Jones, P.A.1
Baylin, S.B.2
-
33
-
-
70350654370
-
DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
-
Broske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M, Kuhl C, Enns A, Prinz M, Jaenisch R, et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet. 2009;41:1207-15.
-
(2009)
Nat Genet
, vol.41
, pp. 1207-1215
-
-
Broske, A.M.1
Vockentanz, L.2
Kharazi, S.3
Huska, M.R.4
Mancini, E.5
Scheller, M.6
Kuhl, C.7
Enns, A.8
Prinz, M.9
Jaenisch, R.10
-
34
-
-
84911004173
-
IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation
-
Liu CC, Lin JH, Hsu TW, Su K, Li AF, Hsu HS, Hung SC. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int J Cancer. 2015;136:547-59.
-
(2015)
Int J Cancer
, vol.136
, pp. 547-559
-
-
Liu, C.C.1
Lin, J.H.2
Hsu, T.W.3
Su, K.4
Li, A.F.5
Hsu, H.S.6
Hung, S.C.7
-
35
-
-
84874501507
-
DNA methyltransferase 1 is essential for initiation of the colon cancers
-
Morita R, Hirohashi Y, Suzuki H, Takahashi A, Tamura Y, Kanaseki T, Asanuma H, Inoda S, Kondo T, Hashino S, et al. DNA methyltransferase 1 is essential for initiation of the colon cancers. Exp Mol Pathol. 2013;94:322-9.
-
(2013)
Exp Mol Pathol
, vol.94
, pp. 322-329
-
-
Morita, R.1
Hirohashi, Y.2
Suzuki, H.3
Takahashi, A.4
Tamura, Y.5
Kanaseki, T.6
Asanuma, H.7
Inoda, S.8
Kondo, T.9
Hashino, S.10
-
36
-
-
84862617605
-
Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells
-
Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R, Kemler R. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012;336:1549-54.
-
(2012)
Science
, vol.336
, pp. 1549-1554
-
-
Hoffmeyer, K.1
Raggioli, A.2
Rudloff, S.3
Anton, R.4
Hierholzer, A.5
Del Valle, I.6
Hein, K.7
Vogt, R.8
Kemler, R.9
-
37
-
-
84878889056
-
ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation
-
Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, Schwitalla S, Kalna G, Ogg EL, Athineos D, et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013;12:761-73.
-
(2013)
Cell Stem Cell
, vol.12
, pp. 761-773
-
-
Myant, K.B.1
Cammareri, P.2
McGhee, E.J.3
Ridgway, R.A.4
Huels, D.J.5
Cordero, J.B.6
Schwitalla, S.7
Kalna, G.8
Ogg, E.L.9
Athineos, D.10
-
38
-
-
33751530490
-
Mining the Wnt pathway for cancer therapeutics
-
Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997-1014.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 997-1014
-
-
Barker, N.1
Clevers, H.2
-
39
-
-
0033895709
-
Wnt signaling and cancer
-
Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837-51.
-
(2000)
Genes Dev
, vol.14
, pp. 1837-1851
-
-
Polakis, P.1
-
40
-
-
36249025636
-
Wnt signaling, stem cells, and the cellular origin of breast cancer
-
Lindvall C, Bu W, Williams BO, Li Y. Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev. 2007;3:157-68.
-
(2007)
Stem Cell Rev
, vol.3
, pp. 157-168
-
-
Lindvall, C.1
Bu, W.2
Williams, B.O.3
Li, Y.4
-
41
-
-
47149097853
-
Epigenetic gene silencing in the Wnt pathway in breast cancer
-
Klarmann GJ, Decker A, Farrar WL. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics. 2008;3:59-63.
-
(2008)
Epigenetics
, vol.3
, pp. 59-63
-
-
Klarmann, G.J.1
Decker, A.2
Farrar, W.L.3
-
42
-
-
12144291274
-
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
-
Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417-22.
-
(2004)
Nat Genet
, vol.36
, pp. 417-422
-
-
Suzuki, H.1
Watkins, D.N.2
Jair, K.W.3
Schuebel, K.E.4
Markowitz, S.D.5
Chen, W.D.6
Pretlow, T.P.7
Yang, B.8
Akiyama, Y.9
Van Engeland, M.10
-
43
-
-
30044442733
-
Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability
-
Koinuma K, Yamashita Y, Liu W, Hatanaka H, Kurashina K, Wada T, Takada S, Kaneda R, Choi YL, Fujiwara SI, et al. Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability. Oncogene. 2006;25:139-46.
-
(2006)
Oncogene
, vol.25
, pp. 139-146
-
-
Koinuma, K.1
Yamashita, Y.2
Liu, W.3
Hatanaka, H.4
Kurashina, K.5
Wada, T.6
Takada, S.7
Kaneda, R.8
Choi, Y.L.9
Fujiwara, S.I.10
-
44
-
-
84916218648
-
Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer
-
Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, Sugiyama T, Katai H, Noshiro H, Ushijima T. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015;18:65-76.
-
(2015)
Gastric Cancer
, vol.18
, pp. 65-76
-
-
Yoda, Y.1
Takeshima, H.2
Niwa, T.3
Kim, J.G.4
Ando, T.5
Kushima, R.6
Sugiyama, T.7
Katai, H.8
Noshiro, H.9
Ushijima, T.10
-
45
-
-
65949116604
-
Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells
-
Hussain M, Rao M, Humphries AE, Hong JA, Liu F, Yang M, Caragacianu D, Schrump DS. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 2009;69:3570-8.
-
(2009)
Cancer Res
, vol.69
, pp. 3570-3578
-
-
Hussain, M.1
Rao, M.2
Humphries, A.E.3
Hong, J.A.4
Liu, F.5
Yang, M.6
Caragacianu, D.7
Schrump, D.S.8
-
46
-
-
44449134715
-
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications
-
Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008;13:529-41.
-
(2008)
Cancer Cell
, vol.13
, pp. 529-541
-
-
Jiang, X.1
Tan, J.2
Li, J.3
Kivimae, S.4
Yang, X.5
Zhuang, L.6
Lee, P.L.7
Chan, M.T.8
Stanton, L.W.9
Liu, E.T.10
-
47
-
-
84878543522
-
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma
-
Rheinbay E, Suva ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013;3:1567-79.
-
(2013)
Cell Rep
, vol.3
, pp. 1567-1579
-
-
Rheinbay, E.1
Suva, M.L.2
Gillespie, S.M.3
Wakimoto, H.4
Patel, A.P.5
Shahid, M.6
Oksuz, O.7
Rabkin, S.D.8
Martuza, R.L.9
Rivera, M.N.10
-
48
-
-
80054774352
-
FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis
-
Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 2011;20:427-42.
-
(2011)
Cancer Cell
, vol.20
, pp. 427-442
-
-
Zhang, N.1
Wei, P.2
Gong, A.3
Chiu, W.T.4
Lee, H.T.5
Colman, H.6
Huang, H.7
Xue, J.8
Liu, M.9
Wang, Y.10
-
49
-
-
77952107413
-
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas
-
Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010;17:497-509.
-
(2010)
Cancer Cell
, vol.17
, pp. 497-509
-
-
Zheng, H.1
Ying, H.2
Wiedemeyer, R.3
Yan, H.4
Quayle, S.N.5
Ivanova, E.V.6
Paik, J.H.7
Zhang, H.8
Xiao, Y.9
Perry, S.R.10
-
50
-
-
84926215418
-
The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling
-
Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell. 2015;16:413-25.
-
(2015)
Cell Stem Cell
, vol.16
, pp. 413-425
-
-
Wang, Y.1
He, L.2
Du, Y.3
Zhu, P.4
Huang, G.5
Luo, J.6
Yan, X.7
Ye, B.8
Li, C.9
Xia, P.10
-
51
-
-
0035577854
-
Hedgehog signaling in animal development: paradigms and principles
-
Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15:3059-87.
-
(2001)
Genes Dev
, vol.15
, pp. 3059-3087
-
-
Ingham, P.W.1
McMahon, A.P.2
-
52
-
-
74949092824
-
Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade
-
Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest. 2010;120:103-14.
-
(2010)
J Clin Invest
, vol.120
, pp. 103-114
-
-
Ma, J.1
Meng, Y.2
Kwiatkowski, D.J.3
Chen, X.4
Peng, H.5
Sun, Q.6
Zha, X.7
Wang, F.8
Wang, Y.9
Jing, Y.10
-
53
-
-
9244221172
-
Tissue repair and stem cell renewal in carcinogenesis
-
Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324-31.
-
(2004)
Nature
, vol.432
, pp. 324-331
-
-
Beachy, P.A.1
Karhadkar, S.S.2
Berman, D.M.3
-
54
-
-
77955443722
-
Hedgehog beyond medulloblastoma and basal cell carcinoma
-
Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 1805;2010:181-208.
-
(1805)
Biochim Biophys Acta
, vol.2010
, pp. 181-208
-
-
Teglund, S.1
Toftgard, R.2
-
55
-
-
77649258546
-
Identification of the cell lineage at the origin of basal cell carcinoma
-
Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA, Blanpain C. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12:299-305.
-
(2010)
Nat Cell Biol
, vol.12
, pp. 299-305
-
-
Youssef, K.K.1
Van Keymeulen, A.2
Lapouge, G.3
Beck, B.4
Michaux, C.5
Achouri, Y.6
Sotiropoulou, P.A.7
Blanpain, C.8
-
56
-
-
79953674198
-
Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers
-
Sellheyer K. Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers. Br J Dermatol. 2011;164:696-711.
-
(2011)
Br J Dermatol
, vol.164
, pp. 696-711
-
-
Sellheyer, K.1
-
57
-
-
48449101742
-
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells
-
Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, Schuller U, Machold R, Fishell G, Rowitch DH, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell. 2008;14:135-45.
-
(2008)
Cancer Cell
, vol.14
, pp. 135-145
-
-
Yang, Z.J.1
Ellis, T.2
Markant, S.L.3
Read, T.A.4
Kessler, J.D.5
Bourboulas, M.6
Schuller, U.7
Machold, R.8
Fishell, G.9
Rowitch, D.H.10
-
58
-
-
48449105147
-
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma
-
Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008;14:123-34.
-
(2008)
Cancer Cell
, vol.14
, pp. 123-134
-
-
Schuller, U.1
Heine, V.M.2
Mao, J.3
Kho, A.T.4
Dillon, A.K.5
Han, Y.G.6
Huillard, E.7
Sun, T.8
Ligon, A.H.9
Qian, Y.10
-
59
-
-
0032940605
-
Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors
-
Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74-9.
-
(1999)
Cancer Res
, vol.59
, pp. 74-79
-
-
Biegel, J.A.1
Zhou, J.Y.2
Rorke, L.B.3
Stenstrom, C.4
Wainwright, L.M.5
Fogelgren, B.6
-
60
-
-
2042432488
-
Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers
-
Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet. 1999;65:1342-8.
-
(1999)
Am J Hum Genet
, vol.65
, pp. 1342-1348
-
-
Sevenet, N.1
Sheridan, E.2
Amram, D.3
Schneider, P.4
Handgretinger, R.5
Delattre, O.6
-
61
-
-
2642647094
-
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
-
Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-6.
-
(1998)
Nature
, vol.394
, pp. 203-206
-
-
Versteege, I.1
Sevenet, N.2
Lange, J.3
Rousseau-Merck, M.F.4
Ambros, P.5
Handgretinger, R.6
Aurias, A.7
Delattre, O.8
-
62
-
-
75949106376
-
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation
-
Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010;12:132-42.
-
(2010)
Nat Cell Biol
, vol.12
, pp. 132-142
-
-
Canettieri, G.1
Di Marcotullio, L.2
Greco, A.3
Coni, S.4
Antonucci, L.5
Infante, P.6
Pietrosanti, L.7
De Smaele, E.8
Ferretti, E.9
Miele, E.10
-
63
-
-
3242722919
-
REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma
-
Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Masuelli L, Napolitano M, Maroder M, et al. REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A. 2004;101:10833-8.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 10833-10838
-
-
Di Marcotullio, L.1
Ferretti, E.2
De Smaele, E.3
Argenti, B.4
Mincione, C.5
Zazzeroni, F.6
Gallo, R.7
Masuelli, L.8
Napolitano, M.9
Maroder, M.10
-
64
-
-
77956051646
-
Expression and regulation mechanisms of Sonic Hedgehog in breast cancer
-
Cui W, Wang LH, Wen YY, Song M, Li BL, Chen XL, Xu M, An SX, Zhao J, Lu YY, et al. Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Sci. 2010;101:927-33.
-
(2010)
Cancer Sci
, vol.101
, pp. 927-933
-
-
Cui, W.1
Wang, L.H.2
Wen, Y.Y.3
Song, M.4
Li, B.L.5
Chen, X.L.6
Xu, M.7
An, S.X.8
Zhao, J.9
Lu, Y.Y.10
-
65
-
-
33646137574
-
Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions
-
Wang LH, Choi YL, Hua XY, Shin YK, Song YJ, Youn SJ, Yun HY, Park SM, Kim WJ, Kim HJ, et al. Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Mod Pathol. 2006;19:675-83.
-
(2006)
Mod Pathol
, vol.19
, pp. 675-683
-
-
Wang, L.H.1
Choi, Y.L.2
Hua, X.Y.3
Shin, Y.K.4
Song, Y.J.5
Youn, S.J.6
Yun, H.Y.7
Park, S.M.8
Kim, W.J.9
Kim, H.J.10
-
66
-
-
84939253368
-
Cooperatively transcriptional and epigenetic regulation of sonic hedgehog overexpression drives malignant potential of breast cancer
-
Duan ZH, Wang HC, Zhao DM, Ji XX, Song M, Yang XJ, Cui W. Cooperatively transcriptional and epigenetic regulation of sonic hedgehog overexpression drives malignant potential of breast cancer. Cancer Sci. 2015;106:1084-91.
-
(2015)
Cancer Sci
, vol.106
, pp. 1084-1091
-
-
Duan, Z.H.1
Wang, H.C.2
Zhao, D.M.3
Ji, X.X.4
Song, M.5
Yang, X.J.6
Cui, W.7
-
67
-
-
84899626029
-
Therapeutic modulation of Notch signalling--are we there yet?
-
Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling--are we there yet? Nat Rev Drug Discov. 2014;13:357-78.
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 357-378
-
-
Andersson, E.R.1
Lendahl, U.2
-
69
-
-
80051531363
-
Notch signaling: simplicity in design, versatility in function
-
Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. Development. 2011;138:3593-612.
-
(2011)
Development
, vol.138
, pp. 3593-3612
-
-
Andersson, E.R.1
Sandberg, R.2
Lendahl, U.3
-
70
-
-
84869880156
-
Epigenetic alterations involved in cancer stem cell reprogramming
-
Munoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol. 2012;6:620-36.
-
(2012)
Mol Oncol
, vol.6
, pp. 620-636
-
-
Munoz, P.1
Iliou, M.S.2
Esteller, M.3
-
71
-
-
77956331142
-
Notch signaling in the regulation of stem cell self-renewal and differentiation
-
Liu J, Sato C, Cerletti M, Wagers A. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol. 2010;92:367-409.
-
(2010)
Curr Top Dev Biol
, vol.92
, pp. 367-409
-
-
Liu, J.1
Sato, C.2
Cerletti, M.3
Wagers, A.4
-
72
-
-
33747513134
-
Notch signalling regulates stem cell numbers in vitro and in vivo
-
Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, Rueger MA, Bae SK, Kittappa R, McKay RD. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442:823-6.
-
(2006)
Nature
, vol.442
, pp. 823-826
-
-
Androutsellis-Theotokis, A.1
Leker, R.R.2
Soldner, F.3
Hoeppner, D.J.4
Ravin, R.5
Poser, S.W.6
Rueger, M.A.7
Bae, S.K.8
Kittappa, R.9
McKay, R.D.10
-
73
-
-
84918533766
-
Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch
-
Lopez-Arribillaga E, Rodilla V, Pellegrinet L, Guiu J, Iglesias M, Roman AC, Gutarra S, Gonzalez S, Munoz-Canoves P, Fernandez-Salguero P, et al. Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch. Development. 2015;142:41-50.
-
(2015)
Development
, vol.142
, pp. 41-50
-
-
Lopez-Arribillaga, E.1
Rodilla, V.2
Pellegrinet, L.3
Guiu, J.4
Iglesias, M.5
Roman, A.C.6
Gutarra, S.7
Gonzalez, S.8
Munoz-Canoves, P.9
Fernandez-Salguero, P.10
-
74
-
-
84924175304
-
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
-
Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S, Chen Y, Wu K. Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014;7:87.
-
(2014)
J Hematol Oncol
, vol.7
, pp. 87
-
-
Yuan, X.1
Wu, H.2
Han, N.3
Xu, H.4
Chu, Q.5
Yu, S.6
Chen, Y.7
Wu, K.8
-
75
-
-
84904749034
-
Notch inhibition allows oncogene-independent generation of iPS cells
-
Ichida JK, Tcw J, Williams LA, Carter AC, Shi Y, Moura MT, Ziller M, Singh S, Amabile G, Bock C, et al. Notch inhibition allows oncogene-independent generation of iPS cells. Nat Chem Biol. 2014;10:632-9.
-
(2014)
Nat Chem Biol
, vol.10
, pp. 632-639
-
-
Ichida, J.K.1
Tcw, J.2
Williams, L.A.3
Carter, A.C.4
Shi, Y.5
Moura, M.T.6
Ziller, M.7
Singh, S.8
Amabile, G.9
Bock, C.10
-
76
-
-
84871821947
-
Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells
-
Zou J, Li P, Lu F, Liu N, Dai J, Ye J, Qu X, Sun X, Ma D, Park J, Ji C. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:3.
-
(2013)
J Hematol Oncol
, vol.6
, pp. 3
-
-
Zou, J.1
Li, P.2
Lu, F.3
Liu, N.4
Dai, J.5
Ye, J.6
Qu, X.7
Sun, X.8
Ma, D.9
Park, J.10
Ji, C.11
-
77
-
-
0030920376
-
The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4)
-
Gallahan D, Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene. 1997;14:1883-90.
-
(1997)
Oncogene
, vol.14
, pp. 1883-1890
-
-
Gallahan, D.1
Callahan, R.2
-
78
-
-
84931410524
-
Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity
-
D'Angelo RC, Ouzounova M, Davis A, Choi D, Tchuenkam SM, Kim G, Luther T, Quraishi AA, Senbabaoglu Y, Conley SJ, et al. Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther. 2015;14:779-87.
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 779-787
-
-
D'Angelo, R.C.1
Ouzounova, M.2
Davis, A.3
Choi, D.4
Tchuenkam, S.M.5
Kim, G.6
Luther, T.7
Quraishi, A.A.8
Senbabaoglu, Y.9
Conley, S.J.10
-
79
-
-
84909609672
-
Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma
-
Wang Z, Da Silva TG, Jin K, Han X, Ranganathan P, Zhu X, Sanchez-Mejias A, Bai F, Li B, Fei DL, et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 2014;74:6364-74.
-
(2014)
Cancer Res
, vol.74
, pp. 6364-6374
-
-
Wang, Z.1
Da Silva, T.G.2
Jin, K.3
Han, X.4
Ranganathan, P.5
Zhu, X.6
Sanchez-Mejias, A.7
Bai, F.8
Li, B.9
Fei, D.L.10
-
80
-
-
85011273914
-
Abstract 1709: STRAP mediates the stemness of human colorectal cancer cells by epigenetic regulation of Notch pathway
-
Jin L, Vu TT, Datta PK. Abstract 1709: STRAP mediates the stemness of human colorectal cancer cells by epigenetic regulation of Notch pathway. Cancer Res. 2016;76:1709.
-
(2016)
Cancer Res
, vol.76
, pp. 1709
-
-
Jin, L.1
Vu, T.T.2
Datta, P.K.3
-
81
-
-
66249085579
-
Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma
-
Ghoshal P, Nganga AJ, Moran-Giuati J, Szafranek A, Johnson TR, Bigelow AJ, Houde CM, Avet-Loiseau H, Smiraglia DJ, Ersing N, et al. Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res. 2009;69:4380-7.
-
(2009)
Cancer Res
, vol.69
, pp. 4380-4387
-
-
Ghoshal, P.1
Nganga, A.J.2
Moran-Giuati, J.3
Szafranek, A.4
Johnson, T.R.5
Bigelow, A.J.6
Houde, C.M.7
Avet-Loiseau, H.8
Smiraglia, D.J.9
Ersing, N.10
-
82
-
-
84938417211
-
EMT and tumor metastasis
-
Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A, Sarkar S. EMT and tumor metastasis. Clin Transl Med. 2015;4:6.
-
(2015)
Clin Transl Med
, vol.4
, pp. 6
-
-
Heerboth, S.1
Housman, G.2
Leary, M.3
Longacre, M.4
Byler, S.5
Lapinska, K.6
Willbanks, A.7
Sarkar, S.8
-
83
-
-
70450198396
-
Epithelial-mesenchymal transitions in development and disease
-
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-90.
-
(2009)
Cell
, vol.139
, pp. 871-890
-
-
Thiery, J.P.1
Acloque, H.2
Huang, R.Y.3
Nieto, M.A.4
-
84
-
-
51449085561
-
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
-
Morel A-P, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition. PLoS One. 2008;3:e2888.
-
(2008)
PLoS One
, vol.3
-
-
Morel, A.-P.1
Lièvre, M.2
Thomas, C.3
Hinkal, G.4
Ansieau, S.5
Puisieux, A.6
-
85
-
-
43049165453
-
The epithelial-mesenchymal transition generates cells with properties of stem cells
-
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-15.
-
(2008)
Cell
, vol.133
, pp. 704-715
-
-
Mani, S.A.1
Guo, W.2
Liao, M.J.3
Eaton, E.N.4
Ayyanan, A.5
Zhou, A.Y.6
Brooks, M.7
Reinhard, F.8
Zhang, C.C.9
Shipitsin, M.10
-
86
-
-
34447131518
-
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition
-
Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282:17259-71.
-
(2007)
J Biol Chem
, vol.282
, pp. 17259-17271
-
-
Dissanayake, S.K.1
Wade, M.2
Johnson, C.E.3
O'Connell, M.P.4
Leotlela, P.D.5
French, A.D.6
Shah, K.V.7
Hewitt, K.J.8
Rosenthal, D.T.9
Indig, F.E.10
-
87
-
-
47549098136
-
The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression
-
Vincan E, Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis. 2008;25:657-63.
-
(2008)
Clin Exp Metastasis
, vol.25
, pp. 657-663
-
-
Vincan, E.1
Barker, N.2
-
88
-
-
47549090432
-
TGFbeta in cancer
-
Massague J. TGFbeta in cancer. Cell. 2008;134:215-30.
-
(2008)
Cell
, vol.134
, pp. 215-230
-
-
Massague, J.1
-
89
-
-
44449144396
-
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis
-
Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818-29.
-
(2008)
Dev Cell
, vol.14
, pp. 818-829
-
-
Yang, J.1
Weinberg, R.A.2
-
90
-
-
33744925683
-
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer
-
Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006;66:5338-45.
-
(2006)
Cancer Res
, vol.66
, pp. 5338-5345
-
-
Dohadwala, M.1
Yang, S.C.2
Luo, J.3
Sharma, S.4
Batra, R.K.5
Huang, M.6
Lin, Y.7
Goodglick, L.8
Krysan, K.9
Fishbein, M.C.10
-
91
-
-
54449085718
-
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers
-
Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A. 2008;105:14867-72.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 14867-14872
-
-
Dumont, N.1
Wilson, M.B.2
Crawford, Y.G.3
Reynolds, P.A.4
Sigaroudinia, M.5
Tlsty, T.D.6
-
92
-
-
70349142665
-
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression
-
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009;23:2140-51.
-
(2009)
Genes Dev
, vol.23
, pp. 2140-2151
-
-
Gibbons, D.L.1
Lin, W.2
Creighton, C.J.3
Rizvi, Z.H.4
Gregory, P.A.5
Goodall, G.J.6
Thilaganathan, N.7
Du, L.8
Zhang, Y.9
Pertsemlidis, A.10
Kurie, J.M.11
-
93
-
-
84957800593
-
The epigenetics of tumour initiation: cancer stem cells and their chromatin
-
Avgustinova A, Benitah SA. The epigenetics of tumour initiation: cancer stem cells and their chromatin. Curr Opin Genet Dev. 2016;36:8-15.
-
(2016)
Curr Opin Genet Dev
, vol.36
, pp. 8-15
-
-
Avgustinova, A.1
Benitah, S.A.2
-
94
-
-
0036848385
-
Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells
-
Koizume S, Tachibana K, Sekiya T, Hirohashi S, Shiraishi M. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res. 2002;30:4770-80.
-
(2002)
Nucleic Acids Res
, vol.30
, pp. 4770-4780
-
-
Koizume, S.1
Tachibana, K.2
Sekiya, T.3
Hirohashi, S.4
Shiraishi, M.5
-
95
-
-
84870745374
-
Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis
-
Wang Y, Shang Y. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res. 2013;319:160-9.
-
(2013)
Exp Cell Res
, vol.319
, pp. 160-169
-
-
Wang, Y.1
Shang, Y.2
-
96
-
-
57649124289
-
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
-
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27:7274-84.
-
(2008)
Oncogene
, vol.27
, pp. 7274-7284
-
-
Cao, Q.1
Yu, J.2
Dhanasekaran, S.M.3
Kim, J.H.4
Mani, R.S.5
Tomlins, S.A.6
Mehra, R.7
Laxman, B.8
Cao, X.9
Yu, J.10
-
97
-
-
47949125993
-
Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor
-
Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, Escriva M, Hernandez-Munoz I, Di Croce L, Helin K, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008;28:4772-81.
-
(2008)
Mol Cell Biol
, vol.28
, pp. 4772-4781
-
-
Herranz, N.1
Pasini, D.2
Diaz, V.M.3
Franci, C.4
Gutierrez, A.5
Dave, N.6
Escriva, M.7
Hernandez-Munoz, I.8
Di Croce, L.9
Helin, K.10
-
98
-
-
43049103824
-
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
-
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593-601.
-
(2008)
Nat Cell Biol
, vol.10
, pp. 593-601
-
-
Gregory, P.A.1
Bert, A.G.2
Paterson, E.L.3
Barry, S.C.4
Tsykin, A.5
Farshid, G.6
Vadas, M.A.7
Khew-Goodall, Y.8
Goodall, G.J.9
-
99
-
-
47249091921
-
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2
-
Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283:14910-4.
-
(2008)
J Biol Chem
, vol.283
, pp. 14910-14914
-
-
Korpal, M.1
Lee, E.S.2
Hu, G.3
Kang, Y.4
-
100
-
-
41649091906
-
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
-
Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22:894-907.
-
(2008)
Genes Dev
, vol.22
, pp. 894-907
-
-
Park, S.M.1
Gaur, A.B.2
Lengyel, E.3
Peter, M.E.4
-
101
-
-
79952283482
-
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs
-
Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011;13:317-23.
-
(2011)
Nat Cell Biol
, vol.13
, pp. 317-323
-
-
Chang, C.J.1
Chao, C.H.2
Xia, W.3
Yang, J.Y.4
Xiong, Y.5
Li, C.W.6
Yu, W.H.7
Rehman, S.K.8
Hsu, J.L.9
Lee, H.H.10
-
102
-
-
79954576652
-
EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells
-
Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011;71:3087-97.
-
(2011)
Cancer Res
, vol.71
, pp. 3087-3097
-
-
Tellez, C.S.1
Juri, D.E.2
Do, K.3
Bernauer, A.M.4
Thomas, C.L.5
Damiani, L.A.6
Tessema, M.7
Leng, S.8
Belinsky, S.A.9
-
103
-
-
36349006961
-
Development and characterization of gemcitabine-resistant pancreatic tumor cells
-
Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629-37.
-
(2007)
Ann Surg Oncol
, vol.14
, pp. 3629-3637
-
-
Shah, A.N.1
Summy, J.M.2
Zhang, J.3
Park, S.I.4
Parikh, N.U.5
Gallick, G.E.6
-
104
-
-
65549141305
-
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway
-
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69:2400-7.
-
(2009)
Cancer Res
, vol.69
, pp. 2400-2407
-
-
Wang, Z.1
Li, Y.2
Kong, D.3
Banerjee, S.4
Ahmad, A.5
Azmi, A.S.6
Ali, S.7
Abbruzzese, J.L.8
Gallick, G.E.9
Sarkar, F.H.10
-
105
-
-
84932196960
-
Epigenetics of cancer stem cells: Pathways and therapeutics
-
Shukla S, Meeran SM. Epigenetics of cancer stem cells: Pathways and therapeutics. Biochim Biophys Acta. 1840;2014:3494-502.
-
(1840)
Biochim Biophys Acta
, vol.2014
, pp. 3494-3502
-
-
Shukla, S.1
Meeran, S.M.2
-
106
-
-
67650999217
-
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
-
Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820-8.
-
(2009)
Cancer Res
, vol.69
, pp. 5820-5828
-
-
Arumugam, T.1
Ramachandran, V.2
Fournier, K.F.3
Wang, H.4
Marquis, L.5
Abbruzzese, J.L.6
Gallick, G.E.7
Logsdon, C.D.8
McConkey, D.J.9
Choi, W.10
-
107
-
-
67650656774
-
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies
-
Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1:93-105.
-
(2008)
Curr Mol Pharmacol
, vol.1
, pp. 93-105
-
-
Wu, C.P.1
Calcagno, A.M.2
Ambudkar, S.V.3
-
108
-
-
84919779810
-
Mohd Abdul Rashid M, Ho D, Chow EK: Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells
-
Wang X, Low XC, Hou W, Abdullah LN, Toh TB. Mohd Abdul Rashid M, Ho D, Chow EK: Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. ACS Nano. 2014;8:12151-66.
-
(2014)
ACS Nano
, vol.8
, pp. 12151-12166
-
-
Wang, X.1
Low, X.C.2
Hou, W.3
Abdullah, L.N.4
Toh, T.B.5
-
109
-
-
84855501388
-
Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells
-
Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, Miele L, Beck WT. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A. 2011;108:20778-83.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 20778-20783
-
-
Cho, S.1
Lu, M.2
He, X.3
Ee, P.L.4
Bhat, U.5
Schneider, E.6
Miele, L.7
Beck, W.T.8
-
110
-
-
84941284340
-
Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy
-
Kim B, Stephen SL, Hanby AM, Horgan K, Perry SL, Richardson J, Roundhill EA, Valleley EM, Verghese ET, Williams BJ, et al. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer. 2015;15:634.
-
(2015)
BMC Cancer
, vol.15
, pp. 634
-
-
Kim, B.1
Stephen, S.L.2
Hanby, A.M.3
Horgan, K.4
Perry, S.L.5
Richardson, J.6
Roundhill, E.A.7
Valleley, E.M.8
Verghese, E.T.9
Williams, B.J.10
-
111
-
-
40749118502
-
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells
-
To KK, Polgar O, Huff LM, Morisaki K, Bates SE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res. 2008;6:151-64.
-
(2008)
Mol Cancer Res
, vol.6
, pp. 151-164
-
-
To, K.K.1
Polgar, O.2
Huff, L.M.3
Morisaki, K.4
Bates, S.E.5
-
113
-
-
43949136445
-
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
-
Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123:8-13.
-
(2008)
Int J Cancer
, vol.123
, pp. 8-13
-
-
Stresemann, C.1
Lyko, F.2
-
114
-
-
0028151343
-
Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
-
Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994;91:11797-801.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 11797-11801
-
-
Juttermann, R.1
Li, E.2
Jaenisch, R.3
-
115
-
-
18944383889
-
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal
-
Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005;25:4727-41.
-
(2005)
Mol Cell Biol
, vol.25
, pp. 4727-4741
-
-
Ghoshal, K.1
Datta, J.2
Majumder, S.3
Bai, S.4
Kutay, H.5
Motiwala, T.6
Jacob, S.T.7
-
116
-
-
0001583359
-
the activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in ak mice
-
Sorm F, Vesely J. the activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in ak mice. Neoplasma. 1964;11:123-30.
-
(1964)
Neoplasma
, vol.11
, pp. 123-130
-
-
Sorm, F.1
Vesely, J.2
-
117
-
-
0023573963
-
The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
-
Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol. 1987;23:1921-4.
-
(1987)
Eur J Cancer Clin Oncol
, vol.23
, pp. 1921-1924
-
-
Abele, R.1
Clavel, M.2
Dodion, P.3
Bruntsch, U.4
Gundersen, S.5
Smyth, J.6
Renard, J.7
van Glabbeke, M.8
Pinedo, H.M.9
-
118
-
-
77954122580
-
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
-
Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics. 2010;2:71-86.
-
(2010)
Epigenomics
, vol.2
, pp. 71-86
-
-
Cowan, L.A.1
Talwar, S.2
Yang, A.S.3
-
119
-
-
0026572102
-
5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group
-
Clavel M, Monfardini S, Fossa S, Smyth J, Renard J, Kaye SB. 5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol. 1992;3:399-400.
-
(1992)
Ann Oncol
, vol.3
, pp. 399-400
-
-
Clavel, M.1
Monfardini, S.2
Fossa, S.3
Smyth, J.4
Renard, J.5
Kaye, S.B.6
-
120
-
-
33749049594
-
A phase II study of depsipeptide in refractory metastatic renal cell cancer
-
Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5:57-60.
-
(2006)
Clin Genitourin Cancer
, vol.5
, pp. 57-60
-
-
Stadler, W.M.1
Margolin, K.2
Ferber, S.3
McCulloch, W.4
Thompson, J.A.5
-
121
-
-
84863337757
-
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells
-
Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:430-46.
-
(2012)
Cancer Cell
, vol.21
, pp. 430-446
-
-
Tsai, H.C.1
Li, H.2
Van Neste, L.3
Cai, Y.4
Robert, C.5
Rassool, F.V.6
Shin, J.J.7
Harbom, K.M.8
Beaty, R.9
Pappou, E.10
-
122
-
-
0024956889
-
5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly
-
Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A, Monfardini S, Colombatti A. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 1989;4 Suppl 3:28-32.
-
(1989)
Bone Marrow Transplant
, vol.4
, pp. 28-32
-
-
Pinto, A.1
Zagonel, V.2
Attadia, V.3
Bullian, P.L.4
Gattei, V.5
Carbone, A.6
Monfardini, S.7
Colombatti, A.8
-
123
-
-
0027221806
-
5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes
-
Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S, Pinto A. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia. 1993;7 Suppl 1:30-5.
-
(1993)
Leukemia
, vol.7
, pp. 30-35
-
-
Zagonel, V.1
Lo Re, G.2
Marotta, G.3
Babare, R.4
Sardeo, G.5
Gattei, V.6
De Angelis, V.7
Monfardini, S.8
Pinto, A.9
-
124
-
-
84869204649
-
Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis
-
Tian J, Lee SO, Liang L, Luo J, Huang CK, Li L, Niu Y, Chang C. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. J Biol Chem. 2012;287:39954-66.
-
(2012)
J Biol Chem
, vol.287
, pp. 39954-39966
-
-
Tian, J.1
Lee, S.O.2
Liang, L.3
Luo, J.4
Huang, C.K.5
Li, L.6
Niu, Y.7
Chang, C.8
-
125
-
-
84907043116
-
Epigenetic targeting of ovarian cancer stem cells
-
Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Nephew KP, Matei D. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014;74:4922-36.
-
(2014)
Cancer Res
, vol.74
, pp. 4922-4936
-
-
Wang, Y.1
Cardenas, H.2
Fang, F.3
Condello, S.4
Taverna, P.5
Segar, M.6
Liu, Y.7
Nephew, K.P.8
Matei, D.9
-
126
-
-
16244400457
-
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension
-
Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10:176-82.
-
(2005)
Oncologist
, vol.10
, pp. 176-182
-
-
Kaminskas, E.1
Farrell, A.T.2
Wang, Y.C.3
Sridhara, R.4
Pazdur, R.5
-
127
-
-
84910082388
-
Small molecule control of chromatin remodeling
-
Finley A, Copeland RA. Small molecule control of chromatin remodeling. Chem Biol. 2014;21:1196-210.
-
(2014)
Chem Biol
, vol.21
, pp. 1196-1210
-
-
Finley, A.1
Copeland, R.A.2
-
128
-
-
0037444803
-
Histone deacetylases (HDACs): characterization of the classical HDAC family
-
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737-49.
-
(2003)
Biochem J
, vol.370
, pp. 737-749
-
-
de Ruijter, A.J.1
van Gennip, A.H.2
Caron, H.N.3
Kemp, S.4
van Kuilenburg, A.B.5
-
129
-
-
0041347519
-
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?
-
Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13-8.
-
(2003)
Cancer Cell
, vol.4
, pp. 13-18
-
-
Johnstone, R.W.1
Licht, J.D.2
-
130
-
-
0031723957
-
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
-
Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185-91.
-
(1998)
Mol Cell Biol
, vol.18
, pp. 7185-7191
-
-
Gelmetti, V.1
Zhang, J.2
Fanelli, M.3
Minucci, S.4
Pelicci, P.G.5
Lazar, M.A.6
-
131
-
-
0034676439
-
Deacetylation of p53 modulates its effect on cell growth and apoptosis
-
Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408:377-81.
-
(2000)
Nature
, vol.408
, pp. 377-381
-
-
Luo, J.1
Su, F.2
Chen, D.3
Shiloh, A.4
Gu, W.5
-
132
-
-
14044276343
-
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas
-
Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 2005;25:1608-19.
-
(2005)
Mol Cell Biol
, vol.25
, pp. 1608-1619
-
-
Duan, H.1
Heckman, C.A.2
Boxer, L.M.3
-
133
-
-
79251541733
-
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors
-
Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol. 2011;2011:475641.
-
(2011)
J Biomed Biotechnol
, vol.2011
, pp. 475641
-
-
Federico, M.1
Bagella, L.2
-
134
-
-
84928889477
-
Epigenetic therapy for solid tumors: from bench science to clinical trials
-
Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, Ahuja N. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics. 2015;7:215-35.
-
(2015)
Epigenomics
, vol.7
, pp. 215-235
-
-
Juo, Y.Y.1
Gong, X.J.2
Mishra, A.3
Cui, X.4
Baylin, S.B.5
Azad, N.S.6
Ahuja, N.7
-
135
-
-
34547683194
-
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
-
Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-15.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3109-3115
-
-
Olsen, E.A.1
Kim, Y.H.2
Kuzel, T.M.3
Pacheco, T.R.4
Foss, F.M.5
Parker, S.6
Frankel, S.R.7
Chen, C.8
Ricker, J.L.9
Arduino, J.M.10
Duvic, M.11
-
136
-
-
73949149251
-
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
-
Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27:5410-7.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5410-5417
-
-
Piekarz, R.L.1
Frye, R.2
Turner, M.3
Wright, J.J.4
Allen, S.L.5
Kirschbaum, M.H.6
Zain, J.7
Prince, H.M.8
Leonard, J.P.9
Geskin, L.J.10
-
137
-
-
84877834926
-
Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications
-
Thaler F. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. Pharm Pat Anal. 2012;1:75-90.
-
(2012)
Pharm Pat Anal
, vol.1
, pp. 75-90
-
-
Thaler, F.1
-
138
-
-
77954879663
-
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma
-
Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485-91.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4485-4491
-
-
Whittaker, S.J.1
Demierre, M.F.2
Kim, E.J.3
Rook, A.H.4
Lerner, A.5
Duvic, M.6
Scarisbrick, J.7
Reddy, S.8
Robak, T.9
Becker, J.C.10
-
139
-
-
50249095068
-
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
-
Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schoffski P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008;26:483-8.
-
(2008)
Invest New Drugs
, vol.26
, pp. 483-488
-
-
Vansteenkiste, J.1
Van Cutsem, E.2
Dumez, H.3
Chen, C.4
Ricker, J.L.5
Randolph, S.S.6
Schoffski, P.7
-
140
-
-
58149242889
-
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study
-
Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008;14:7138-42.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7138-7142
-
-
Luu, T.H.1
Morgan, R.J.2
Leong, L.3
Lim, D.4
McNamara, M.5
Portnow, J.6
Frankel, P.7
Smith, D.D.8
Doroshow, J.H.9
Wong, C.10
-
141
-
-
58149387609
-
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma
-
Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2009;94:164-70.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 164-170
-
-
Woyach, J.A.1
Kloos, R.T.2
Ringel, M.D.3
Arbogast, D.4
Collamore, M.5
Zwiebel, J.A.6
Grever, M.7
Villalona-Calero, M.8
Shah, M.H.9
-
142
-
-
43049091153
-
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
-
Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182-6.
-
(2008)
Gynecol Oncol
, vol.109
, pp. 182-186
-
-
Modesitt, S.C.1
Sill, M.2
Hoffman, J.S.3
Bender, D.P.4
-
143
-
-
38149140216
-
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
-
Blumenschein Jr GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008;26:81-7.
-
(2008)
Invest New Drugs
, vol.26
, pp. 81-87
-
-
Blumenschein, G.R.1
Kies, M.S.2
Papadimitrakopoulou, V.A.3
Lu, C.4
Kumar, A.J.5
Ricker, J.L.6
Chiao, J.H.7
Chen, C.8
Frankel, S.R.9
-
144
-
-
67649399669
-
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study
-
Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol. 2009;4:522-6.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 522-526
-
-
Traynor, A.M.1
Dubey, S.2
Eickhoff, J.C.3
Kolesar, J.M.4
Schell, K.5
Huie, M.S.6
Groteluschen, D.L.7
Marcotte, S.M.8
Hallahan, C.M.9
Weeks, H.R.10
-
145
-
-
65349141942
-
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
-
Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009;27:2052-8.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2052-2058
-
-
Galanis, E.1
Jaeckle, K.A.2
Maurer, M.J.3
Reid, J.M.4
Ames, M.M.5
Hardwick, J.S.6
Reilly, J.F.7
Loboda, A.8
Nebozhyn, M.9
Fantin, V.R.10
-
146
-
-
40749101544
-
Clinical and molecular responses in lung cancer patients receiving Romidepsin
-
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res. 2008;14:188-98.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 188-198
-
-
Schrump, D.S.1
Fischette, M.R.2
Nguyen, D.M.3
Zhao, M.4
Li, X.5
Kunst, T.F.6
Hancox, A.7
Hong, J.A.8
Chen, G.A.9
Kruchin, E.10
-
147
-
-
77958185126
-
Cancer, Leukemia Group B: Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)
-
Otterson GA, Hodgson L, Pang H, Vokes EE. Cancer, Leukemia Group B: Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010;5:1644-8.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1644-1648
-
-
Otterson, G.A.1
Hodgson, L.2
Pang, H.3
Vokes, E.E.4
-
148
-
-
79959956310
-
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
-
Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011;13:509-16.
-
(2011)
Neuro Oncol
, vol.13
, pp. 509-516
-
-
Iwamoto, F.M.1
Lamborn, K.R.2
Kuhn, J.G.3
Wen, P.Y.4
Yung, W.K.5
Gilbert, M.R.6
Chang, S.M.7
Lieberman, F.S.8
Prados, M.D.9
Fine, H.A.10
-
149
-
-
68649119641
-
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
-
Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL, Blanke CD. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009;27:469-75.
-
(2009)
Invest New Drugs
, vol.27
, pp. 469-475
-
-
Whitehead, R.P.1
Rankin, C.2
Hoff, P.M.3
Gold, P.J.4
Billingsley, K.G.5
Chapman, R.A.6
Wong, L.7
Ward, J.H.8
Abbruzzese, J.L.9
Blanke, C.D.10
-
150
-
-
70549105748
-
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
-
Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs Jr CE, Higano C, Stadler WM, McCulloch W, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010;21:109-13.
-
(2010)
Ann Oncol
, vol.21
, pp. 109-113
-
-
Molife, L.R.1
Attard, G.2
Fong, P.C.3
Karavasilis, V.4
Reid, A.H.5
Patterson, S.6
Riggs, C.E.7
Higano, C.8
Stadler, W.M.9
McCulloch, W.10
-
151
-
-
84892949427
-
Harnessing the potential of epigenetic therapy to target solid tumors
-
Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest. 2014;124:56-63.
-
(2014)
J Clin Invest
, vol.124
, pp. 56-63
-
-
Ahuja, N.1
Easwaran, H.2
Baylin, S.B.3
-
152
-
-
84892942381
-
New and emerging HDAC inhibitors for cancer treatment
-
West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30-9.
-
(2014)
J Clin Invest
, vol.124
, pp. 30-39
-
-
West, A.C.1
Johnstone, R.W.2
-
153
-
-
73949128107
-
Histone deacetylase inhibitors in cancer therapy
-
Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459-68.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5459-5468
-
-
Lane, A.A.1
Chabner, B.A.2
-
154
-
-
84891350230
-
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
-
Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A. Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Res. 2013;33:4475-81.
-
(2013)
Anticancer Res
, vol.33
, pp. 4475-4481
-
-
Tarhini, A.A.1
Zahoor, H.2
McLaughlin, B.3
Gooding, W.E.4
Schmitz, J.C.5
Siegfried, J.M.6
Socinski, M.A.7
Argiris, A.8
-
155
-
-
84883187700
-
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
-
Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, Ray-Coquard I, Chabaud S, Penel N, Berge Y, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013;109:909-14.
-
(2013)
Br J Cancer
, vol.109
, pp. 909-914
-
-
Cassier, P.A.1
Lefranc, A.2
Amela, E.Y.3
Chevreau, C.4
Bui, B.N.5
Lecesne, A.6
Ray-Coquard, I.7
Chabaud, S.8
Penel, N.9
Berge, Y.10
-
156
-
-
84864004796
-
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy
-
Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn Jr PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012;30:2248-55.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2248-2255
-
-
Witta, S.E.1
Jotte, R.M.2
Konduri, K.3
Neubauer, M.A.4
Spira, A.I.5
Ruxer, R.L.6
Varella-Garcia, M.7
Bunn, P.A.8
Hirsch, F.R.9
-
157
-
-
84879834815
-
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor
-
Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31:2128-35.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2128-2135
-
-
Yardley, D.A.1
Ismail-Khan, R.R.2
Melichar, B.3
Lichinitser, M.4
Munster, P.N.5
Klein, P.M.6
Cruickshank, S.7
Miller, K.D.8
Lee, M.J.9
Trepel, J.B.10
-
158
-
-
84866758581
-
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group
-
Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group. J Clin Oncol. 2012;30:3361-7.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3361-3367
-
-
Yeo, W.1
Chung, H.C.2
Chan, S.L.3
Wang, L.Z.4
Lim, R.5
Picus, J.6
Boyer, M.7
Mo, F.K.8
Koh, J.9
Rha, S.Y.10
-
159
-
-
84863419977
-
a phase ii evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a gynecologic oncology group study
-
Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM, Disilvestro PA, Fader AN. a phase ii evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;125:367-71.
-
(2012)
Gynecol Oncol
, vol.125
, pp. 367-371
-
-
Dizon, D.S.1
Blessing, J.A.2
Penson, R.T.3
Drake, R.D.4
Walker, J.L.5
Johnston, C.M.6
Disilvestro, P.A.7
Fader, A.N.8
-
160
-
-
84883806177
-
A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
-
Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer. 2013;60:1868-74.
-
(2013)
Pediatr Blood Cancer
, vol.60
, pp. 1868-1874
-
-
Zorzi, A.P.1
Bernstein, M.2
Samson, Y.3
Wall, D.A.4
Desai, S.5
Nicksy, D.6
Wainman, N.7
Eisenhauer, E.8
Baruchel, S.9
-
161
-
-
77950809059
-
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
-
Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69-80.
-
(2010)
Cell
, vol.141
, pp. 69-80
-
-
Sharma, S.V.1
Lee, D.Y.2
Li, B.3
Quinlan, M.P.4
Takahashi, F.5
Maheswaran, S.6
McDermott, U.7
Azizian, N.8
Zou, L.9
Fischbach, M.A.10
-
162
-
-
18244383806
-
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
-
Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo j. 2001;20:6969-78.
-
(2001)
Embo j
, vol.20
, pp. 6969-6978
-
-
Gottlicher, M.1
Minucci, S.2
Zhu, P.3
Kramer, O.H.4
Schimpf, A.5
Giavara, S.6
Sleeman, J.P.7
Lo Coco, F.8
Nervi, C.9
Pelicci, P.G.10
Heinzel, T.11
-
163
-
-
55949105764
-
Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status
-
Travaglini L, Vian L, Billi M, Grignani F, Nervi C. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol. 2009;41:225-34.
-
(2009)
Int J Biochem Cell Biol
, vol.41
, pp. 225-234
-
-
Travaglini, L.1
Vian, L.2
Billi, M.3
Grignani, F.4
Nervi, C.5
-
164
-
-
84942110039
-
Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
-
Schech A, Kazi A, Yu S, Shah P, Sabnis G. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. Mol Cancer Ther. 2015;14:1848-57.
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 1848-1857
-
-
Schech, A.1
Kazi, A.2
Yu, S.3
Shah, P.4
Sabnis, G.5
-
165
-
-
84975789841
-
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives
-
Song Y, Wu F, Wu J. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol. 2016;9:49.
-
(2016)
J Hematol Oncol
, vol.9
, pp. 49
-
-
Song, Y.1
Wu, F.2
Wu, J.3
-
166
-
-
84864434739
-
Emerging epigenetic targets and therapies in cancer medicine
-
Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2012;2:405-13.
-
(2012)
Cancer Discov
, vol.2
, pp. 405-413
-
-
Popovic, R.1
Licht, J.D.2
-
167
-
-
69949148388
-
Protein methyltransferases as a target class for drug discovery
-
Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009;8:724-32.
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 724-732
-
-
Copeland, R.A.1
Solomon, M.E.2
Richon, V.M.3
-
168
-
-
35848951163
-
Covalent modifications of histones during development and disease pathogenesis
-
Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol. 2007;14:1008-16.
-
(2007)
Nat Struct Mol Biol
, vol.14
, pp. 1008-1016
-
-
Bhaumik, S.R.1
Smith, E.2
Shilatifard, A.3
-
169
-
-
84868101932
-
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L
-
Basavapathruni A, Jin L, Daigle SR, Majer CR, Therkelsen CA, Wigle TJ, Kuntz KW, Chesworth R, Pollock RM, Scott MP, et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des. 2012;80:971-80.
-
(2012)
Chem Biol Drug Des
, vol.80
, pp. 971-980
-
-
Basavapathruni, A.1
Jin, L.2
Daigle, S.R.3
Majer, C.R.4
Therkelsen, C.A.5
Wigle, T.J.6
Kuntz, K.W.7
Chesworth, R.8
Pollock, R.M.9
Scott, M.P.10
-
170
-
-
84905254858
-
Epigenetic targets and drug discovery: part 1: histone methylation
-
Liu Y, Liu K, Qin S, Xu C, Min J. Epigenetic targets and drug discovery: part 1: histone methylation. Pharmacol Ther. 2014;143:275-94.
-
(2014)
Pharmacol Ther
, vol.143
, pp. 275-294
-
-
Liu, Y.1
Liu, K.2
Qin, S.3
Xu, C.4
Min, J.5
-
171
-
-
84930212511
-
Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation
-
Liu K, Liu Y, Lau JL, Min J. Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation. Pharmacol Ther. 2015;151:121-40.
-
(2015)
Pharmacol Ther
, vol.151
, pp. 121-140
-
-
Liu, K.1
Liu, Y.2
Lau, J.L.3
Min, J.4
-
172
-
-
84928383804
-
Targeting histone lysine methylation in cancer
-
McGrath J, Trojer P. Targeting histone lysine methylation in cancer. Pharmacol Ther. 2015;150:1-22.
-
(2015)
Pharmacol Ther
, vol.150
, pp. 1-22
-
-
McGrath, J.1
Trojer, P.2
-
173
-
-
84874789539
-
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
-
Copeland RA, Moyer MP, Richon VM. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene. 2013;32:939-46.
-
(2013)
Oncogene
, vol.32
, pp. 939-946
-
-
Copeland, R.A.1
Moyer, M.P.2
Richon, V.M.3
-
174
-
-
42149146774
-
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells
-
Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, Schupp M, Zhuo D, Vakoc AL, Kim JE, Chen J, Lazar MA, et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol. 2008;28:2825-39.
-
(2008)
Mol Cell Biol
, vol.28
, pp. 2825-2839
-
-
Steger, D.J.1
Lefterova, M.I.2
Ying, L.3
Stonestrom, A.J.4
Schupp, M.5
Zhuo, D.6
Vakoc, A.L.7
Kim, J.E.8
Chen, J.9
Lazar, M.A.10
-
175
-
-
46249112085
-
Combinatorial patterns of histone acetylations and methylations in the human genome
-
Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40:897-903.
-
(2008)
Nat Genet
, vol.40
, pp. 897-903
-
-
Wang, Z.1
Zang, C.2
Rosenfeld, J.A.3
Schones, D.E.4
Barski, A.5
Cuddapah, S.6
Cui, K.7
Roh, T.Y.8
Peng, W.9
Zhang, M.Q.10
Zhao, K.11
-
176
-
-
39649084473
-
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
-
Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, Zhou R, Nesvizhskii A, Chinnaiyan A, Hess JL, Slany RK. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007;110:4445-54.
-
(2007)
Blood
, vol.110
, pp. 4445-4454
-
-
Mueller, D.1
Bach, C.2
Zeisig, D.3
Garcia-Cuellar, M.P.4
Monroe, S.5
Sreekumar, A.6
Zhou, R.7
Nesvizhskii, A.8
Chinnaiyan, A.9
Hess, J.L.10
Slany, R.K.11
-
177
-
-
33846522525
-
The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling
-
Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet. 2007;16:92-106.
-
(2007)
Hum Mol Genet
, vol.16
, pp. 92-106
-
-
Bitoun, E.1
Oliver, P.L.2
Davies, K.E.3
-
178
-
-
33745873838
-
Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner
-
Zhang W, Xia X, Reisenauer MR, Hemenway CS, Kone BC. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem. 2006;281:18059-68.
-
(2006)
J Biol Chem
, vol.281
, pp. 18059-18068
-
-
Zhang, W.1
Xia, X.2
Reisenauer, M.R.3
Hemenway, C.S.4
Kone, B.C.5
-
179
-
-
17444375685
-
hDOT1L links histone methylation to leukemogenesis
-
Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121:167-78.
-
(2005)
Cell
, vol.121
, pp. 167-178
-
-
Okada, Y.1
Feng, Q.2
Lin, Y.3
Jiang, Q.4
Li, Y.5
Coffield, V.M.6
Su, L.7
Xu, G.8
Zhang, Y.9
-
180
-
-
54549083228
-
H3K79 methylation profiles define murine and human MLL-AF4 leukemias
-
Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14:355-68.
-
(2008)
Cancer Cell
, vol.14
, pp. 355-368
-
-
Krivtsov, A.V.1
Feng, Z.2
Lemieux, M.E.3
Faber, J.4
Vempati, S.5
Sinha, A.U.6
Xia, X.7
Jesneck, J.8
Bracken, A.P.9
Silverman, L.B.10
-
181
-
-
79960058024
-
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
-
Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20:53-65.
-
(2011)
Cancer Cell
, vol.20
, pp. 53-65
-
-
Daigle, S.R.1
Olhava, E.J.2
Therkelsen, C.A.3
Majer, C.R.4
Sneeringer, C.J.5
Song, J.6
Johnston, L.D.7
Scott, M.P.8
Smith, J.J.9
Xiao, Y.10
-
182
-
-
84886864184
-
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
-
Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122:1017-25.
-
(2013)
Blood
, vol.122
, pp. 1017-1025
-
-
Daigle, S.R.1
Olhava, E.J.2
Therkelsen, C.A.3
Basavapathruni, A.4
Jin, L.5
Boriack-Sjodin, P.A.6
Allain, C.J.7
Klaus, C.R.8
Raimondi, A.9
Scott, M.P.10
-
183
-
-
0036830642
-
Role of histone H3 lysine 27 methylation in Polycomb-group silencing
-
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039-43.
-
(2002)
Science
, vol.298
, pp. 1039-1043
-
-
Cao, R.1
Wang, L.2
Wang, H.3
Xia, L.4
Erdjument-Bromage, H.5
Tempst, P.6
Jones, R.S.7
Zhang, Y.8
-
184
-
-
18644383738
-
Histone methyltransferase activity of a Drosophila Polycomb group repressor complex
-
Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE, Simon JA. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002;111:197-208.
-
(2002)
Cell
, vol.111
, pp. 197-208
-
-
Muller, J.1
Hart, C.M.2
Francis, N.J.3
Vargas, M.L.4
Sengupta, A.5
Wild, B.6
Miller, E.L.7
O'Connor, M.B.8
Kingston, R.E.9
Simon, J.A.10
-
185
-
-
0037111831
-
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein
-
Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002;16:2893-905.
-
(2002)
Genes Dev
, vol.16
, pp. 2893-2905
-
-
Kuzmichev, A.1
Nishioka, K.2
Erdjument-Bromage, H.3
Tempst, P.4
Reinberg, D.5
-
186
-
-
84954430798
-
Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis
-
Wang X, Zhao H, Lv L, Bao L, Wang X, Han S. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis. Sci Rep. 2016;6:19239.
-
(2016)
Sci Rep
, vol.6
, pp. 19239
-
-
Wang, X.1
Zhao, H.2
Lv, L.3
Bao, L.4
Wang, X.5
Han, S.6
-
187
-
-
0141816752
-
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
-
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100:11606-11.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 11606-11611
-
-
Kleer, C.G.1
Cao, Q.2
Varambally, S.3
Shen, R.4
Ota, I.5
Tomlins, S.A.6
Ghosh, D.7
Sewalt, R.G.8
Otte, A.P.9
Hayes, D.F.10
-
188
-
-
55949136562
-
Roles of the EZH2 histone methyltransferase in cancer epigenetics
-
Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21-9.
-
(2008)
Mutat Res
, vol.647
, pp. 21-29
-
-
Simon, J.A.1
Lange, C.A.2
-
189
-
-
84891921366
-
The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
-
Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang W, Wang D, Ye J, Jiang H, Yang J, Cheng J. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget. 2013;4:2532-49.
-
(2013)
Oncotarget
, vol.4
, pp. 2532-2549
-
-
Li, Z.1
Wang, Y.2
Qiu, J.3
Li, Q.4
Yuan, C.5
Zhang, W.6
Wang, D.7
Ye, J.8
Jiang, H.9
Yang, J.10
Cheng, J.11
-
190
-
-
18644382388
-
The polycomb group protein EZH2 is involved in progression of prostate cancer
-
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-9.
-
(2002)
Nature
, vol.419
, pp. 624-629
-
-
Varambally, S.1
Dhanasekaran, S.M.2
Zhou, M.3
Barrette, T.R.4
Kumar-Sinha, C.5
Sanda, M.G.6
Ghosh, D.7
Pienta, K.J.8
Sewalt, R.G.9
Otte, A.P.10
-
191
-
-
29344439946
-
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas
-
Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, Krause H. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med. 2005;16:349-53.
-
(2005)
Int J Mol Med
, vol.16
, pp. 349-353
-
-
Weikert, S.1
Christoph, F.2
Kollermann, J.3
Muller, M.4
Schrader, M.5
Miller, K.6
Krause, H.7
-
192
-
-
84874106911
-
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia
-
Shi J, Wang E, Zuber J, Rappaport A, Taylor M, Johns C, Lowe SW, Vakoc CR. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene. 2013;32:930-8.
-
(2013)
Oncogene
, vol.32
, pp. 930-938
-
-
Shi, J.1
Wang, E.2
Zuber, J.3
Rappaport, A.4
Taylor, M.5
Johns, C.6
Lowe, S.W.7
Vakoc, C.R.8
-
193
-
-
73649102464
-
EZH2 is essential for glioblastoma cancer stem cell maintenance
-
Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009;69:9211-8.
-
(2009)
Cancer Res
, vol.69
, pp. 9211-9218
-
-
Suva, M.L.1
Riggi, N.2
Janiszewska, M.3
Radovanovic, I.4
Provero, P.5
Stehle, J.C.6
Baumer, K.7
Bitoux, M.A.8
Marino, D.9
Cironi, L.10
-
194
-
-
33646870495
-
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions
-
Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123-36.
-
(2006)
Genes Dev
, vol.20
, pp. 1123-1136
-
-
Bracken, A.P.1
Dietrich, N.2
Pasini, D.3
Hansen, K.H.4
Helin, K.5
-
195
-
-
67649371461
-
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
-
Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009;8:1579-88.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1579-1588
-
-
Miranda, T.B.1
Cortez, C.C.2
Yoo, C.B.3
Liang, G.4
Abe, M.5
Kelly, T.K.6
Marquez, V.E.7
Jones, P.A.8
-
196
-
-
84877324084
-
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
-
Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110:7922-7.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 7922-7927
-
-
Knutson, S.K.1
Warholic, N.M.2
Wigle, T.J.3
Klaus, C.R.4
Allain, C.J.5
Raimondi, A.6
Porter Scott, M.7
Chesworth, R.8
Moyer, M.P.9
Copeland, R.A.10
-
197
-
-
84921318899
-
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma
-
Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13:842-54.
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 842-854
-
-
Knutson, S.K.1
Kawano, S.2
Minoshima, Y.3
Warholic, N.M.4
Huang, K.C.5
Xiao, Y.6
Kadowaki, T.7
Uesugi, M.8
Kuznetsov, G.9
Kumar, N.10
-
198
-
-
84870573126
-
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
-
McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra 3rd A, Diaz E, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108-12.
-
(2012)
Nature
, vol.492
, pp. 108-112
-
-
McCabe, M.T.1
Ott, H.M.2
Ganji, G.3
Korenchuk, S.4
Thompson, C.5
Aller, G.S.6
Liu, Y.7
Graves, A.P.8
Della Pietra, A.9
Diaz, E.10
-
199
-
-
84959090816
-
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A
-
Chen YT, Zhu F, Lin WR, Ying RB, Yang YP, Zeng LH. The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother Pharmacol. 2016;77:757-65.
-
(2016)
Cancer Chemother Pharmacol
, vol.77
, pp. 757-765
-
-
Chen, Y.T.1
Zhu, F.2
Lin, W.R.3
Ying, R.B.4
Yang, Y.P.5
Zeng, L.H.6
-
200
-
-
84896928662
-
Long residence time inhibition of EZH2 in activated polycomb repressive complex 2
-
Van Aller GS, Pappalardi MB, Ott HM, Diaz E, Brandt M, Schwartz BJ, Miller WH, Dhanak D, McCabe MT, Verma SK, et al. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem Biol. 2014;9:622-9.
-
(2014)
ACS Chem Biol
, vol.9
, pp. 622-629
-
-
Aller, G.S.1
Pappalardi, M.B.2
Ott, H.M.3
Diaz, E.4
Brandt, M.5
Schwartz, B.J.6
Miller, W.H.7
Dhanak, D.8
McCabe, M.T.9
Verma, S.K.10
-
201
-
-
0037099413
-
G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis
-
Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H, Shinkai Y. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002;16:1779-91.
-
(2002)
Genes Dev
, vol.16
, pp. 1779-1791
-
-
Tachibana, M.1
Sugimoto, K.2
Nozaki, M.3
Ueda, J.4
Ohta, T.5
Ohki, M.6
Fukuda, M.7
Takeda, N.8
Niida, H.9
Kato, H.10
Shinkai, Y.11
-
202
-
-
77951233574
-
G9a and Glp methylate lysine 373 in the tumor suppressor p53
-
Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, Reinberg D, Berger SL. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010;285:9636-41.
-
(2010)
J Biol Chem
, vol.285
, pp. 9636-9641
-
-
Huang, J.1
Dorsey, J.2
Chuikov, S.3
Perez-Burgos, L.4
Zhang, X.5
Jenuwein, T.6
Reinberg, D.7
Berger, S.L.8
-
203
-
-
44249128891
-
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells
-
Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JP. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One. 2008;3:e2037.
-
(2008)
PLoS One
, vol.3
-
-
Kondo, Y.1
Shen, L.2
Ahmed, S.3
Boumber, Y.4
Sekido, Y.5
Haddad, B.R.6
Issa, J.P.7
-
204
-
-
34548645031
-
Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas
-
Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res. 2007;37:974-83.
-
(2007)
Hepatol Res
, vol.37
, pp. 974-983
-
-
Kondo, Y.1
Shen, L.2
Suzuki, S.3
Kurokawa, T.4
Masuko, K.5
Tanaka, Y.6
Kato, H.7
Mizuno, Y.8
Yokoe, M.9
Sugauchi, F.10
-
205
-
-
78049307486
-
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM
-
Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010;70:7830-40.
-
(2010)
Cancer Res
, vol.70
, pp. 7830-7840
-
-
Chen, M.W.1
Hua, K.T.2
Kao, H.J.3
Chi, C.C.4
Wei, L.H.5
Johansson, G.6
Shiah, S.G.7
Chen, P.S.8
Jeng, Y.M.9
Cheng, T.Y.10
-
206
-
-
80051543424
-
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1
-
Cho HS, Kelly JD, Hayami S, Toyokawa G, Takawa M, Yoshimatsu M, Tsunoda T, Field HI, Neal DE, Ponder BA, et al. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia. 2011;13:676-84.
-
(2011)
Neoplasia
, vol.13
, pp. 676-684
-
-
Cho, H.S.1
Kelly, J.D.2
Hayami, S.3
Toyokawa, G.4
Takawa, M.5
Yoshimatsu, M.6
Tsunoda, T.7
Field, H.I.8
Neal, D.E.9
Ponder, B.A.10
-
207
-
-
84908342064
-
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis
-
Hua KT, Wang MY, Chen MW, Wei LH, Chen CK, Ko CH, Jeng YM, Sung PL, Jan YH, Hsiao M, et al. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer. 2014;13:189.
-
(2014)
Mol Cancer
, vol.13
, pp. 189
-
-
Hua, K.T.1
Wang, M.Y.2
Chen, M.W.3
Wei, L.H.4
Chen, C.K.5
Ko, C.H.6
Jeng, Y.M.7
Sung, P.L.8
Jan, Y.H.9
Hsiao, M.10
-
208
-
-
84958205887
-
Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months
-
Bai K, Cao Y, Huang C, Chen J, Zhang X, Jiang Y. Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months. Medicine (Baltimore). 2016;95:e2493.
-
(2016)
Medicine (Baltimore)
, vol.95
-
-
Bai, K.1
Cao, Y.2
Huang, C.3
Chen, J.4
Zhang, X.5
Jiang, Y.6
-
209
-
-
33846783261
-
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
-
Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, Rea S, Mechtler K, Kowalski JA, Homon CA, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007;25:473-81.
-
(2007)
Mol Cell
, vol.25
, pp. 473-481
-
-
Kubicek, S.1
O'Sullivan, R.J.2
August, E.M.3
Hickey, E.R.4
Zhang, Q.5
Teodoro, M.L.6
Rea, S.7
Mechtler, K.8
Kowalski, J.A.9
Homon, C.A.10
-
210
-
-
67649800263
-
Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins
-
Trojer P, Zhang J, Yonezawa M, Schmidt A, Zheng H, Jenuwein T, Reinberg D. Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins. J Biol Chem. 2009;284:8395-405.
-
(2009)
J Biol Chem
, vol.284
, pp. 8395-8405
-
-
Trojer, P.1
Zhang, J.2
Yonezawa, M.3
Schmidt, A.4
Zheng, H.5
Jenuwein, T.6
Reinberg, D.7
-
211
-
-
74249105659
-
Essential role of the histone methyltransferase G9a in cocaine-induced plasticity
-
Maze I, Covington 3rd HE, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science. 2010;327:213-6.
-
(2010)
Science
, vol.327
, pp. 213-216
-
-
Maze, I.1
Covington, H.E.2
Dietz, D.M.3
LaPlant, Q.4
Renthal, W.5
Russo, S.J.6
Mechanic, M.7
Mouzon, E.8
Neve, R.L.9
Haggarty, S.J.10
-
212
-
-
84890834128
-
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production
-
Kim Y, Kim YS, Kim DE, Lee JS, Song JH, Kim HG, Cho DH, Jeong SY, Jin DH, Jang SJ, et al. BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production. Autophagy. 2013;9:2126-39.
-
(2013)
Autophagy
, vol.9
, pp. 2126-2139
-
-
Kim, Y.1
Kim, Y.S.2
Kim, D.E.3
Lee, J.S.4
Song, J.H.5
Kim, H.G.6
Cho, D.H.7
Jeong, S.Y.8
Jin, D.H.9
Jang, S.J.10
-
213
-
-
79960493567
-
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
-
Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011;7:566-74.
-
(2011)
Nat Chem Biol
, vol.7
, pp. 566-574
-
-
Vedadi, M.1
Barsyte-Lovejoy, D.2
Liu, F.3
Rival-Gervier, S.4
Allali-Hassani, A.5
Labrie, V.6
Wigle, T.J.7
Dimaggio, P.A.8
Wasney, G.A.9
Siarheyeva, A.10
-
214
-
-
84887923349
-
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP
-
Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, Allali-Hassani A, Janzen WP, Roth BL, Frye SV, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013;56:8931-42.
-
(2013)
J Med Chem
, vol.56
, pp. 8931-8942
-
-
Liu, F.1
Barsyte-Lovejoy, D.2
Li, F.3
Xiong, Y.4
Korboukh, V.5
Huang, X.P.6
Allali-Hassani, A.7
Janzen, W.P.8
Roth, B.L.9
Frye, S.V.10
-
215
-
-
75749102137
-
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition
-
Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene. 2010;29:576-88.
-
(2010)
Oncogene
, vol.29
, pp. 576-588
-
-
Lakshmikuttyamma, A.1
Scott, S.A.2
DeCoteau, J.F.3
Geyer, C.R.4
-
216
-
-
85011274021
-
Inhibition of SUV39H Methyltransferase As a Potent Therapeutic Target in Multiple Myeloma
-
Devin J, Viziteu E, Herviou L, Seckinger A, Camille G, Goldschmidt H, Vincent L, Pasero P, Hose D, Klein B, Moreaux J. Inhibition of SUV39H Methyltransferase As a Potent Therapeutic Target in Multiple Myeloma. Blood. 2015;126:1771.
-
(2015)
Blood
, vol.126
, pp. 1771
-
-
Devin, J.1
Viziteu, E.2
Herviou, L.3
Seckinger, A.4
Camille, G.5
Goldschmidt, H.6
Vincent, L.7
Pasero, P.8
Hose, D.9
Klein, B.10
Moreaux, J.11
-
217
-
-
84989315935
-
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells
-
Lai YS, Chen JY, Tsai HJ, Chen TY, Hung WC. The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells. Blood Cancer J. 2015;5:e313.
-
(2015)
Blood Cancer J
, vol.5
-
-
Lai, Y.S.1
Chen, J.Y.2
Tsai, H.J.3
Chen, T.Y.4
Hung, W.C.5
-
218
-
-
84922273765
-
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma
-
Chiba T, Saito T, Yuki K, Zen Y, Koide S, Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, et al. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer. 2015;136:289-98.
-
(2015)
Int J Cancer
, vol.136
, pp. 289-298
-
-
Chiba, T.1
Saito, T.2
Yuki, K.3
Zen, Y.4
Koide, S.5
Kanogawa, N.6
Motoyama, T.7
Ogasawara, S.8
Suzuki, E.9
Ooka, Y.10
-
219
-
-
84954396146
-
Histone demethylases in chromatin biology and beyond
-
Dimitrova E, Turberfield AH, Klose RJ. Histone demethylases in chromatin biology and beyond. EMBO Rep. 2015;16:1620-39.
-
(2015)
EMBO Rep
, vol.16
, pp. 1620-1639
-
-
Dimitrova, E.1
Turberfield, A.H.2
Klose, R.J.3
-
220
-
-
84889573275
-
Histone lysine demethylases as targets for anticancer therapy
-
Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12:917-30.
-
(2013)
Nat Rev Drug Discov
, vol.12
, pp. 917-930
-
-
Hojfeldt, J.W.1
Agger, K.2
Helin, K.3
-
221
-
-
84860371953
-
Epigenetic protein families: a new frontier for drug discovery
-
Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11:384-400.
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 384-400
-
-
Arrowsmith, C.H.1
Bountra, C.2
Fish, P.V.3
Lee, K.4
Schapira, M.5
-
222
-
-
33747455678
-
JmjC-domain-containing proteins and histone demethylation
-
Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7:715-27.
-
(2006)
Nat Rev Genet
, vol.7
, pp. 715-727
-
-
Klose, R.J.1
Kallin, E.M.2
Zhang, Y.3
-
223
-
-
84862123313
-
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
-
Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21:473-87.
-
(2012)
Cancer Cell
, vol.21
, pp. 473-487
-
-
Harris, W.J.1
Huang, X.2
Lynch, J.T.3
Spencer, G.J.4
Hitchin, J.R.5
Li, Y.6
Ciceri, F.7
Blaser, J.G.8
Greystoke, B.F.9
Jordan, A.M.10
-
224
-
-
84886410044
-
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines
-
Konovalov S, Garcia-Bassets I. Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines. J Ovarian Res. 2013;6:75.
-
(2013)
J Ovarian Res
, vol.6
, pp. 75
-
-
Konovalov, S.1
Garcia-Bassets, I.2
-
226
-
-
84862777766
-
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
-
Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18:605-11.
-
(2012)
Nat Med
, vol.18
, pp. 605-611
-
-
Schenk, T.1
Chen, W.C.2
Gollner, S.3
Howell, L.4
Jin, L.5
Hebestreit, K.6
Klein, H.U.7
Popescu, A.C.8
Burnett, A.9
Mills, K.10
-
227
-
-
84886815629
-
Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia
-
Maes T, Tirapu I, Mascaró C, Ortega A, Estiarte A, Valls N, Castro-Palomino J, Arjol CB, Kurz G. Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. J Clin Oncol. 2013;31:e13543.
-
(2013)
J Clin Oncol
, vol.31
-
-
Maes, T.1
Tirapu, I.2
Mascaró, C.3
Ortega, A.4
Estiarte, A.5
Valls, N.6
Castro-Palomino, J.7
Arjol, C.B.8
Kurz, G.9
-
228
-
-
84991771838
-
Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia
-
Mohammad H, Smitheman K, Cusan M, Liu Y, Pappalardi M, Federowicz K, Van Aller G, Kasparec J, Tian X, Suarez D, et al. Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia. Blood. 2013;122:3964.
-
(2013)
Blood
, vol.122
, pp. 3964
-
-
Mohammad, H.1
Smitheman, K.2
Cusan, M.3
Liu, Y.4
Pappalardi, M.5
Federowicz, K.6
Aller, G.7
Kasparec, J.8
Tian, X.9
Suarez, D.10
-
229
-
-
35348812522
-
LSD1 and the chemistry of histone demethylation
-
Culhane JC, Cole PA. LSD1 and the chemistry of histone demethylation. Curr Opin Chem Biol. 2007;11:561-8.
-
(2007)
Curr Opin Chem Biol
, vol.11
, pp. 561-568
-
-
Culhane, J.C.1
Cole, P.A.2
-
230
-
-
84865864630
-
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
-
Sprussel A, Schulte JH, Weber S, Necke M, Handschke K, Thor T, Pajtler KW, Schramm A, Konig K, Diehl L, et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia. 2012;26:2039-51.
-
(2012)
Leukemia
, vol.26
, pp. 2039-2051
-
-
Sprussel, A.1
Schulte, J.H.2
Weber, S.3
Necke, M.4
Handschke, K.5
Thor, T.6
Pajtler, K.W.7
Schramm, A.8
Konig, K.9
Diehl, L.10
-
231
-
-
84937429405
-
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
-
Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015;28:57-69.
-
(2015)
Cancer Cell
, vol.28
, pp. 57-69
-
-
Mohammad, H.P.1
Smitheman, K.N.2
Kamat, C.D.3
Soong, D.4
Federowicz, K.E.5
Aller, G.S.6
Schneck, J.L.7
Carson, J.D.8
Liu, Y.9
Butticello, M.10
-
232
-
-
35148898348
-
A histone H3 lysine 27 demethylase regulates animal posterior development
-
Lan F, Bayliss PE, Rinn JL, Whetstine JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Canaani E, et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature. 2007;449:689-94.
-
(2007)
Nature
, vol.449
, pp. 689-694
-
-
Lan, F.1
Bayliss, P.E.2
Rinn, J.L.3
Whetstine, J.R.4
Wang, J.K.5
Chen, S.6
Iwase, S.7
Alpatov, R.8
Issaeva, I.9
Canaani, E.10
-
233
-
-
35148867907
-
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development
-
Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007;449:731-4.
-
(2007)
Nature
, vol.449
, pp. 731-734
-
-
Agger, K.1
Cloos, P.A.2
Christensen, J.3
Pasini, D.4
Rose, S.5
Rappsilber, J.6
Issaeva, I.7
Canaani, E.8
Salcini, A.E.9
Helin, K.10
-
234
-
-
35348993743
-
Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination
-
Lee MG, Villa R, Trojer P, Norman J, Yan KP, Reinberg D, Di Croce L, Shiekhattar R. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science. 2007;318:447-50.
-
(2007)
Science
, vol.318
, pp. 447-450
-
-
Lee, M.G.1
Villa, R.2
Trojer, P.3
Norman, J.4
Yan, K.P.5
Reinberg, D.6
Croce, L.7
Shiekhattar, R.8
-
235
-
-
33847219608
-
Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth
-
Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenbach L, Canaani E. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol Cell Biol. 2007;27:1889-903.
-
(2007)
Mol Cell Biol
, vol.27
, pp. 1889-1903
-
-
Issaeva, I.1
Zonis, Y.2
Rozovskaia, T.3
Orlovsky, K.4
Croce, C.M.5
Nakamura, T.6
Mazo, A.7
Eisenbach, L.8
Canaani, E.9
-
236
-
-
34547122520
-
PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex
-
Cho YW, Hong T, Hong S, Guo H, Yu H, Kim D, Guszczynski T, Dressler GR, Copeland TD, Kalkum M, Ge K. PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J Biol Chem. 2007;282:20395-406.
-
(2007)
J Biol Chem
, vol.282
, pp. 20395-20406
-
-
Cho, Y.W.1
Hong, T.2
Hong, S.3
Guo, H.4
Yu, H.5
Kim, D.6
Guszczynski, T.7
Dressler, G.R.8
Copeland, T.D.9
Kalkum, M.10
Ge, K.11
-
237
-
-
78649263390
-
Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression
-
Miller SA, Mohn SE, Weinmann AS. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Mol Cell. 2010;40:594-605.
-
(2010)
Mol Cell
, vol.40
, pp. 594-605
-
-
Miller, S.A.1
Mohn, S.E.2
Weinmann, A.S.3
-
238
-
-
84925625370
-
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
-
Fu LL, Tian M, Li X, Li JJ, Huang J, Ouyang L, Zhang Y, Liu B. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget. 2015;6:5501-16.
-
(2015)
Oncotarget
, vol.6
, pp. 5501-5516
-
-
Fu, L.L.1
Tian, M.2
Li, X.3
Li, J.J.4
Huang, J.5
Ouyang, L.6
Zhang, Y.7
Liu, B.8
-
239
-
-
78650847770
-
Selective inhibition of BET bromodomains
-
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067-73.
-
(2010)
Nature
, vol.468
, pp. 1067-1073
-
-
Filippakopoulos, P.1
Qi, J.2
Picaud, S.3
Shen, Y.4
Smith, W.B.5
Fedorov, O.6
Morse, E.M.7
Keates, T.8
Hickman, T.T.9
Felletar, I.10
-
240
-
-
80052955256
-
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
-
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904-17.
-
(2011)
Cell
, vol.146
, pp. 904-917
-
-
Delmore, J.E.1
Issa, G.C.2
Lemieux, M.E.3
Rahl, P.B.4
Shi, J.5
Jacobs, H.M.6
Kastritis, E.7
Gilpatrick, T.8
Paranal, R.M.9
Qi, J.10
-
241
-
-
84903814369
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer
-
Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014;24:809-19.
-
(2014)
Cell Res
, vol.24
, pp. 809-819
-
-
Feng, Q.1
Zhang, Z.2
Shea, M.J.3
Creighton, C.J.4
Coarfa, C.5
Hilsenbeck, S.G.6
Lanz, R.7
He, B.8
Wang, L.9
Fu, X.10
-
242
-
-
84930278597
-
Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing
-
Rajagopalan V, Vaidyanathan M, Janardhanam VA, Bradner JE. Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing. Cell Mol Neurobiol. 2014;34:1059-69.
-
(2014)
Cell Mol Neurobiol
, vol.34
, pp. 1059-1069
-
-
Rajagopalan, V.1
Vaidyanathan, M.2
Janardhanam, V.A.3
Bradner, J.E.4
-
243
-
-
78650806593
-
Suppression of inflammation by a synthetic histone mimic
-
Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119-23.
-
(2010)
Nature
, vol.468
, pp. 1119-1123
-
-
Nicodeme, E.1
Jeffrey, K.L.2
Schaefer, U.3
Beinke, S.4
Dewell, S.5
Chung, C.W.6
Chandwani, R.7
Marazzi, I.8
Wilson, P.9
Coste, H.10
-
244
-
-
84907894098
-
The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor
-
Gosmini R, Nguyen VL, Toum J, Simon C, Brusq JM, Krysa G, Mirguet O, Riou-Eymard AM, Boursier EV, Trottet L, et al. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem. 2014;57:8111-31.
-
(2014)
J Med Chem
, vol.57
, pp. 8111-8131
-
-
Gosmini, R.1
Nguyen, V.L.2
Toum, J.3
Simon, C.4
Brusq, J.M.5
Krysa, G.6
Mirguet, O.7
Riou-Eymard, A.M.8
Boursier, E.V.9
Trottet, L.10
-
246
-
-
84891921969
-
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
-
Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, McHugh CF, Vessella R, Creasy CL, Tummino PJ, Barbash O. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget. 2013;4:2419-29.
-
(2013)
Oncotarget
, vol.4
, pp. 2419-2429
-
-
Wyce, A.1
Degenhardt, Y.2
Bai, Y.3
Le, B.4
Korenchuk, S.5
Crouthame, M.C.6
McHugh, C.F.7
Vessella, R.8
Creasy, C.L.9
Tummino, P.J.10
Barbash, O.11
-
247
-
-
84883012780
-
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models
-
Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, Barbash O, Le B, Craggs PD, McCabe MT, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One. 2013;8:e72967.
-
(2013)
PLoS One
, vol.8
-
-
Wyce, A.1
Ganji, G.2
Smitheman, K.N.3
Chung, C.W.4
Korenchuk, S.5
Bai, Y.6
Barbash, O.7
Le, B.8
Craggs, P.D.9
McCabe, M.T.10
-
248
-
-
84942516634
-
Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
-
Herait PE, Berthon C, Thieblemont C, Raffoux E, Magarotto V, Stathis A, Thomas X, Leleu X, Gomez-Roca C, Odore E, et al. Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Cancer Res. 2014;74:CT231.
-
(2014)
Cancer Res
, vol.74
-
-
Herait, P.E.1
Berthon, C.2
Thieblemont, C.3
Raffoux, E.4
Magarotto, V.5
Stathis, A.6
Thomas, X.7
Leleu, X.8
Gomez-Roca, C.9
Odore, E.10
-
249
-
-
84893189613
-
528 The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL)
-
Bonetti P, Ponzoni M, Tibiletti MG, Stathis A, Heirat P, Zucca E, Bertoni F. 528 The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL). Eur J Cancer. 2012;48:163.
-
(2012)
Eur J Cancer.
, vol.48
, pp. 163
-
-
Bonetti, P.1
Ponzoni, M.2
Tibiletti, M.G.3
Stathis, A.4
Heirat, P.5
Zucca, E.6
Bertoni, F.7
-
250
-
-
84897024898
-
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
-
Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014;123:697-705.
-
(2014)
Blood
, vol.123
, pp. 697-705
-
-
Chaidos, A.1
Caputo, V.2
Gouvedenou, K.3
Liu, B.4
Marigo, I.5
Chaudhry, M.S.6
Rotolo, A.7
Tough, D.F.8
Smithers, N.N.9
Bassil, A.K.10
-
251
-
-
84975078260
-
Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth
-
Pathania R, Ramachandran S, Mariappan G, Thakur P, Shi H, Choi J-H, Manicassamy S, Kolhe R, Prasad PD, Sharma S, et al. Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. Cancer Res. 2016;76:3224-35.
-
(2016)
Cancer Res
, vol.76
, pp. 3224-3235
-
-
Pathania, R.1
Ramachandran, S.2
Mariappan, G.3
Thakur, P.4
Shi, H.5
Choi, J.-H.6
Manicassamy, S.7
Kolhe, R.8
Prasad, P.D.9
Sharma, S.10
-
252
-
-
84655163371
-
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer
-
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1:598-607.
-
(2011)
Cancer Discov
, vol.1
, pp. 598-607
-
-
Juergens, R.A.1
Wrangle, J.2
Vendetti, F.P.3
Murphy, S.C.4
Zhao, M.5
Coleman, B.6
Sebree, R.7
Rodgers, K.8
Hooker, C.M.9
Franco, N.10
-
253
-
-
59149095188
-
Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice
-
Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen SA, et al. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009;69:887-95.
-
(2009)
Cancer Res
, vol.69
, pp. 887-895
-
-
Ecke, I.1
Petry, F.2
Rosenberger, A.3
Tauber, S.4
Monkemeyer, S.5
Hess, I.6
Dullin, C.7
Kimmina, S.8
Pirngruber, J.9
Johnsen, S.A.10
-
254
-
-
84939526901
-
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
-
Curry E, Green I, Chapman-Rothe N, Shamsaei E, Kandil S, Cherblanc FL, Payne L, Bell E, Ganesh T, Srimongkolpithak N, et al. Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. Clin Epigenetics. 2015;7:84.
-
(2015)
Clin Epigenetics
, vol.7
, pp. 84
-
-
Curry, E.1
Green, I.2
Chapman-Rothe, N.3
Shamsaei, E.4
Kandil, S.5
Cherblanc, F.L.6
Payne, L.7
Bell, E.8
Ganesh, T.9
Srimongkolpithak, N.10
-
255
-
-
84907291965
-
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells
-
Klaus CR, Iwanowicz D, Johnston D, Campbell CA, Smith JJ, Moyer MP, Copeland RA, Olhava EJ, Scott MP, Pollock RM, et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014;350:646-56.
-
(2014)
J Pharmacol Exp Ther
, vol.350
, pp. 646-656
-
-
Klaus, C.R.1
Iwanowicz, D.2
Johnston, D.3
Campbell, C.A.4
Smith, J.J.5
Moyer, M.P.6
Copeland, R.A.7
Olhava, E.J.8
Scott, M.P.9
Pollock, R.M.10
-
256
-
-
84901853867
-
Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance
-
Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54:716-27.
-
(2014)
Mol Cell
, vol.54
, pp. 716-727
-
-
Easwaran, H.1
Tsai, H.C.2
Baylin, S.B.3
-
257
-
-
84975075182
-
Improving Sensitivity to Irinotecan Using 5-Azacytidine in Colon Cancer Cell Lines
-
Vatapalli RJ, Guzzetta AA, Fu T, Syed LH, Kwak R, Ahuja N. Improving Sensitivity to Irinotecan Using 5-Azacytidine in Colon Cancer Cell Lines. J Surgical Res. 2013;179:251-252.
-
(2013)
J Surgical Res.
, vol.179
, pp. 251-252
-
-
Vatapalli, R.J.1
Guzzetta, A.A.2
Fu, T.3
Syed, L.H.4
Kwak, R.5
Ahuja, N.6
-
258
-
-
79952266135
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
-
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011;117:1661-9.
-
(2011)
Cancer
, vol.117
, pp. 1661-1669
-
-
Fu, S.1
Hu, W.2
Iyer, R.3
Kavanagh, J.J.4
Coleman, R.L.5
Levenback, C.F.6
Sood, A.K.7
Wolf, J.K.8
Gershenson, D.M.9
Markman, M.10
-
259
-
-
34548414620
-
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
-
Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25:4603-9.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4603-4609
-
-
Appleton, K.1
Mackay, H.J.2
Judson, I.3
Plumb, J.A.4
McCormick, C.5
Strathdee, G.6
Lee, C.7
Barrett, S.8
Reade, S.9
Jadayel, D.10
-
260
-
-
84860528199
-
Epigenetic resensitization to platinum in ovarian cancer
-
Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012;72:2197-205.
-
(2012)
Cancer Res
, vol.72
, pp. 2197-2205
-
-
Matei, D.1
Fang, F.2
Shen, C.3
Schilder, J.4
Arnold, A.5
Zeng, Y.6
Berry, W.A.7
Huang, T.8
Nephew, K.P.9
-
261
-
-
84865168464
-
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
-
Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, et al. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2012;132:1063-72.
-
(2012)
Breast Cancer Res Treat
, vol.132
, pp. 1063-1072
-
-
Ramaswamy, B.1
Fiskus, W.2
Cohen, B.3
Pellegrino, C.4
Hershman, D.L.5
Chuang, E.6
Luu, T.7
Somlo, G.8
Goetz, M.9
Swaby, R.10
-
262
-
-
84926456748
-
Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells
-
Li SY, Sun R, Wang HX, Shen S, Liu Y, Du XJ, Zhu YH, Jun W. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release. 2015;205:7-14.
-
(2015)
J Control Release
, vol.205
, pp. 7-14
-
-
Li, S.Y.1
Sun, R.2
Wang, H.X.3
Shen, S.4
Liu, Y.5
Du, X.J.6
Zhu, Y.H.7
Jun, W.8
-
264
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
-
265
-
-
13744253833
-
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
-
Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307-14.
-
(2005)
Cancer Immunol Immunother
, vol.54
, pp. 307-314
-
-
Blank, C.1
Gajewski, T.F.2
Mackensen, A.3
-
266
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
Powderly, J.D.7
Carvajal, R.D.8
Sosman, J.A.9
Atkins, M.B.10
-
267
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
Drake, C.G.7
Camacho, L.H.8
Kauh, J.9
Odunsi, K.10
-
268
-
-
84931560629
-
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
-
Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y, Chang AE, Wicha MS. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells. 2015;33:2085-92.
-
(2015)
Stem Cells
, vol.33
, pp. 2085-2092
-
-
Pan, Q.1
Li, Q.2
Liu, S.3
Ning, N.4
Zhang, X.5
Xu, Y.6
Chang, A.E.7
Wicha, M.S.8
-
269
-
-
84940473692
-
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models
-
Covre A, Coral S, Nicolay H, Parisi G, Fazio C, Colizzi F, Fratta E, Di Giacomo AM, Sigalotti L, Natali PG, Maio M. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology. 2015;4:e1019978.
-
(2015)
Oncoimmunology
, vol.4
-
-
Covre, A.1
Coral, S.2
Nicolay, H.3
Parisi, G.4
Fazio, C.5
Colizzi, F.6
Fratta, E.7
Giacomo, A.M.8
Sigalotti, L.9
Natali, P.G.10
Maio, M.11
-
270
-
-
84905994658
-
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
-
Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz Jr LA, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014;111:11774-9.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 11774-11779
-
-
Kim, K.1
Skora, A.D.2
Li, Z.3
Liu, Q.4
Tam, A.J.5
Blosser, R.L.6
Diaz, L.A.7
Papadopoulos, N.8
Kinzler, K.W.9
Vogelstein, B.10
Zhou, S.11
-
271
-
-
79951735484
-
Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics
-
Qifeng S, Bo C, Xingtao J, Chuanliang P, Xiaogang Z. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics. J Thorac Cardiovasc Surg. 2011;141:808-14.
-
(2011)
J Thorac Cardiovasc Surg
, vol.141
, pp. 808-814
-
-
Qifeng, S.1
Bo, C.2
Xingtao, J.3
Chuanliang, P.4
Xiaogang, Z.5
-
272
-
-
72649095844
-
Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer
-
Ye Q, Shen Y, Wang X, Yang J, Miao F, Shen C, Zhang J. Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens. 2010;75:30-9.
-
(2010)
Tissue Antigens
, vol.75
, pp. 30-39
-
-
Ye, Q.1
Shen, Y.2
Wang, X.3
Yang, J.4
Miao, F.5
Shen, C.6
Zhang, J.7
-
273
-
-
34447102893
-
Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition
-
Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol. 2007;178:692-6.
-
(2007)
J Urol
, vol.178
, pp. 692-696
-
-
Kitamura, H.1
Torigoe, T.2
Asanuma, H.3
Honma, I.4
Sato, N.5
Tsukamoto, T.6
-
274
-
-
0034671618
-
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors
-
Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000;165:7017-24.
-
(2000)
J Immunol
, vol.165
, pp. 7017-7024
-
-
Magner, W.J.1
Kazim, A.L.2
Stewart, C.3
Romano, M.A.4
Catalano, G.5
Grande, C.6
Keiser, N.7
Santaniello, F.8
Tomasi, T.B.9
-
275
-
-
33846862931
-
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
-
Mora-Garcia Mde L, Duenas-Gonzalez A, Hernandez-Montes J, De la Cruz-Hernandez E, Perez-Cardenas E, Weiss-Steider B, Santiago-Osorio E, Ortiz-Navarrete VF, Rosales VH, Cantu D, et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med. 2006;4:55.
-
(2006)
J Transl Med
, vol.4
, pp. 55
-
-
Mora-Garcia Mde, L.1
Duenas-Gonzalez, A.2
Hernandez-Montes, J.3
Cruz-Hernandez, E.4
Perez-Cardenas, E.5
Weiss-Steider, B.6
Santiago-Osorio, E.7
Ortiz-Navarrete, V.F.8
Rosales, V.H.9
Cantu, D.10
-
276
-
-
84896820241
-
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
-
Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587-98.
-
(2014)
Oncotarget
, vol.5
, pp. 587-598
-
-
Li, H.1
Chiappinelli, K.B.2
Guzzetta, A.A.3
Easwaran, H.4
Yen, R.W.5
Vatapalli, R.6
Topper, M.J.7
Luo, J.8
Connolly, R.M.9
Azad, N.S.10
-
277
-
-
84877574817
-
The future of epigenetic therapy in solid tumours--lessons from the past
-
Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013;10:256-66.
-
(2013)
Nat Rev Clin Oncol
, vol.10
, pp. 256-266
-
-
Azad, N.1
Zahnow, C.A.2
Rudin, C.M.3
Baylin, S.B.4
-
278
-
-
79952667434
-
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
-
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117:2697-702.
-
(2011)
Cancer
, vol.117
, pp. 2697-2702
-
-
Silverman, L.R.1
Fenaux, P.2
Mufti, G.J.3
Santini, V.4
Hellstrom-Lindberg, E.5
Gattermann, N.6
Sanz, G.7
List, A.F.8
Gore, S.D.9
Seymour, J.F.10
-
279
-
-
84930541141
-
SGI-110: DNA Methyltransferase Inhibitor Oncolytic
-
Griffiths EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR. SGI-110: DNA Methyltransferase Inhibitor Oncolytic. Drugs Future. 2013;38:535-43.
-
(2013)
Drugs Future
, vol.38
, pp. 535-543
-
-
Griffiths, E.A.1
Choy, G.2
Redkar, S.3
Taverna, P.4
Azab, M.5
Karpf, A.R.6
-
280
-
-
84940600974
-
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
-
Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1099-110.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1099-1110
-
-
Issa, J.P.1
Roboz, G.2
Rizzieri, D.3
Jabbour, E.4
Stock, W.5
O'Connell, C.6
Yee, K.7
Tibes, R.8
Griffiths, E.A.9
Walsh, K.10
-
281
-
-
84919769943
-
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer
-
Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res. 2014;20:6504-16.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 6504-6516
-
-
Fang, F.1
Munck, J.2
Tang, J.3
Taverna, P.4
Wang, Y.5
Miller, D.F.6
Pilrose, J.7
Choy, G.8
Azab, M.9
Pawelczak, K.S.10
-
282
-
-
84864024420
-
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study
-
Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197-203.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2197-2203
-
-
Younes, A.1
Sureda, A.2
Ben-Yehuda, D.3
Zinzani, P.L.4
Ong, T.C.5
Prince, H.M.6
Harrison, S.J.7
Kirschbaum, M.8
Johnston, P.9
Gallagher, J.10
-
283
-
-
84872107995
-
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial
-
Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbe C, Assaf C, Squier M, Williams D, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49:386-94.
-
(2013)
Eur J Cancer
, vol.49
, pp. 386-394
-
-
Duvic, M.1
Dummer, R.2
Becker, J.C.3
Poulalhon, N.4
Ortiz Romero, P.5
Grazia Bernengo, M.6
Lebbe, C.7
Assaf, C.8
Squier, M.9
Williams, D.10
-
284
-
-
84980417467
-
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
-
Batlevi CL, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorensen R, Ordentlich P, Cruickshank S, Kunkel L, et al. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica. 2016;101:968-75.
-
(2016)
Haematologica
, vol.101
, pp. 968-975
-
-
Batlevi, C.L.1
Kasamon, Y.2
Bociek, R.G.3
Lee, P.4
Gore, L.5
Copeland, A.6
Sorensen, R.7
Ordentlich, P.8
Cruickshank, S.9
Kunkel, L.10
-
285
-
-
84907689730
-
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
-
Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014;55:2301-4.
-
(2014)
Leuk Lymphoma
, vol.55
, pp. 2301-2304
-
-
Kirschbaum, M.H.1
Foon, K.A.2
Frankel, P.3
Ruel, C.4
Pulone, B.5
Tuscano, J.M.6
Newman, E.M.7
-
286
-
-
84940562761
-
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
-
O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015;33:2492-9.
-
(2015)
J Clin Oncol
, vol.33
, pp. 2492-2499
-
-
O'Connor, O.A.1
Horwitz, S.2
Masszi, T.3
Hoof, A.4
Brown, P.5
Doorduijn, J.6
Hess, G.7
Jurczak, W.8
Knoblauch, P.9
Chawla, S.10
-
287
-
-
77952585540
-
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
-
Mackay HJ, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P, Wang L, Mason J, Pham PA, Tsao MS, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010;46:1573-9.
-
(2010)
Eur J Cancer
, vol.46
, pp. 1573-1579
-
-
Mackay, H.J.1
Hirte, H.2
Colgan, T.3
Covens, A.4
MacAlpine, K.5
Grenci, P.6
Wang, L.7
Mason, J.8
Pham, P.A.9
Tsao, M.S.10
-
288
-
-
84929085702
-
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200dagger
-
Chu QS, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowling M, et al. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200dagger. Ann Oncol. 2015;26:973-81.
-
(2015)
Ann Oncol
, vol.26
, pp. 973-981
-
-
Chu, Q.S.1
Nielsen, T.O.2
Alcindor, T.3
Gupta, A.4
Endo, M.5
Goytain, A.6
Xu, H.7
Verma, S.8
Tozer, R.9
Knowling, M.10
-
289
-
-
84944441620
-
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
-
Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, et al. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs. 2015;33:969-76.
-
(2015)
Invest New Drugs
, vol.33
, pp. 969-976
-
-
Eigl, B.J.1
North, S.2
Winquist, E.3
Finch, D.4
Wood, L.5
Sridhar, S.S.6
Powers, J.7
Good, J.8
Sharma, M.9
Squire, J.A.10
-
290
-
-
77955168425
-
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
-
Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150:446-55.
-
(2010)
Br J Haematol
, vol.150
, pp. 446-455
-
-
Rambaldi, A.1
Dellacasa, C.M.2
Finazzi, G.3
Carobbio, A.4
Ferrari, M.L.5
Guglielmelli, P.6
Gattoni, E.7
Salmoiraghi, S.8
Finazzi, M.C.9
Tollo, S.10
-
291
-
-
84982746744
-
Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation
-
Mawatari T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K, Makino I, Nakagawara H, Miyashita T, Tajima H, et al. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol. 2015;47:2073-81.
-
(2015)
Int J Oncol
, vol.47
, pp. 2073-2081
-
-
Mawatari, T.1
Ninomiya, I.2
Inokuchi, M.3
Harada, S.4
Hayashi, H.5
Oyama, K.6
Makino, I.7
Nakagawara, H.8
Miyashita, T.9
Tajima, H.10
-
292
-
-
34247625135
-
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
-
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050-63.
-
(2007)
Genes Dev
, vol.21
, pp. 1050-1063
-
-
Tan, J.1
Yang, X.2
Zhuang, L.3
Jiang, X.4
Chen, W.5
Lee, P.L.6
Karuturi, R.K.7
Tan, P.B.8
Liu, E.T.9
Yu, Q.10
-
293
-
-
79955119487
-
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
-
Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011;10:40.
-
(2011)
Mol Cancer
, vol.10
, pp. 40
-
-
Crea, F.1
Hurt, E.M.2
Mathews, L.A.3
Cabarcas, S.M.4
Sun, L.5
Marquez, V.E.6
Danesi, R.7
Farrar, W.L.8
-
294
-
-
84911462255
-
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation
-
Bradley WD, Arora S, Busby J, Balasubramanian S, Gehling VS, Nasveschuk CG, Vaswani RG, Yuan CC, Hatton C, Zhao F, et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014;21:1463-75.
-
(2014)
Chem Biol
, vol.21
, pp. 1463-1475
-
-
Bradley, W.D.1
Arora, S.2
Busby, J.3
Balasubramanian, S.4
Gehling, V.S.5
Nasveschuk, C.G.6
Vaswani, R.G.7
Yuan, C.C.8
Hatton, C.9
Zhao, F.10
-
295
-
-
84865120905
-
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
-
Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012;488:404-8.
-
(2012)
Nature
, vol.488
, pp. 404-408
-
-
Kruidenier, L.1
Chung, C.W.2
Cheng, Z.3
Liddle, J.4
Che, K.5
Joberty, G.6
Bantscheff, M.7
Bountra, C.8
Bridges, A.9
Diallo, H.10
-
296
-
-
80053651202
-
Targeting MYC dependence in cancer by inhibiting BET bromodomains
-
Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims 3rd RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108:16669-74.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 16669-16674
-
-
Mertz, J.A.1
Conery, A.R.2
Bryant, B.M.3
Sandy, P.4
Balasubramanian, S.5
Mele, D.A.6
Bergeron, L.7
Sims, R.J.8
-
297
-
-
84891953718
-
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma
-
Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777-90.
-
(2013)
Cancer Cell
, vol.24
, pp. 777-790
-
-
Chapuy, B.1
McKeown, M.R.2
Lin, C.Y.3
Monti, S.4
Roemer, M.G.5
Qi, J.6
Rahl, P.B.7
Sun, H.H.8
Yeda, K.T.9
Doench, J.G.10
-
298
-
-
80054984945
-
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
-
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478:529-33.
-
(2011)
Nature
, vol.478
, pp. 529-533
-
-
Dawson, M.A.1
Prinjha, R.K.2
Dittmann, A.3
Giotopoulos, G.4
Bantscheff, M.5
Chan, W.I.6
Robson, S.C.7
Chung, C.W.8
Hopf, C.9
Savitski, M.M.10
-
299
-
-
84919473753
-
The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers
-
Long J, Li B, Rodriguez-Blanco J, Pastori C, Volmar CH, Wahlestedt C, Capobianco A, Bai F, Pei XH, Ayad NG, Robbins DJ. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem. 2014;289:35494-502.
-
(2014)
J Biol Chem
, vol.289
, pp. 35494-35502
-
-
Long, J.1
Li, B.2
Rodriguez-Blanco, J.3
Pastori, C.4
Volmar, C.H.5
Wahlestedt, C.6
Capobianco, A.7
Bai, F.8
Pei, X.H.9
Ayad, N.G.10
Robbins, D.J.11
-
300
-
-
84921725084
-
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
-
Moros A, Rodriguez V, Saborit-Villarroya I, Montraveta A, Balsas P, Sandy P, Martinez A, Wiestner A, Normant E, Campo E, et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014;28:2049-59.
-
(2014)
Leukemia
, vol.28
, pp. 2049-2059
-
-
Moros, A.1
Rodriguez, V.2
Saborit-Villarroya, I.3
Montraveta, A.4
Balsas, P.5
Sandy, P.6
Martinez, A.7
Wiestner, A.8
Normant, E.9
Campo, E.10
-
301
-
-
84959440884
-
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
-
Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Cote A, Leblanc Y, Nasveschuk CG, Bellon S, Bergeron L, Campbell R, et al. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. J Med Chem. 2016;59:1330-9.
-
(2016)
J Med Chem
, vol.59
, pp. 1330-1339
-
-
Albrecht, B.K.1
Gehling, V.S.2
Hewitt, M.C.3
Vaswani, R.G.4
Cote, A.5
Leblanc, Y.6
Nasveschuk, C.G.7
Bellon, S.8
Bergeron, L.9
Campbell, R.10
|